Broadly neutralizing anti-HIV antibodies

By developing a broadly neutralizing anti-HIV antibody that recognizes the gp120 carbohydrate-dependent epitope, the problem of insufficient antibody specificity and activity in existing technologies has been solved, achieving effective neutralization and protective immune response against HIV.

CN118955699APending Publication Date: 2024-11-15THE ROCKEFELLER UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410516500.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2012-10-18
Filing Date
2013-10-18
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

In the current technology, little is known about the specificity and activity of broadly neutralizing anti-HIV antibodies, making it difficult to effectively inhibit HIV infection, and the protective effect of these antibodies in existing vaccines is limited.

Method used

A novel broadly neutralizing anti-HIV antibody was developed by designing an antibody with a specific CDR sequence to enhance neutralizing activity by recognizing carbohydrate-dependent epitopes on gp120, including complex N-glycans.

Benefits of technology

It provides anti-HIV antibodies with broad neutralizing activity, effectively neutralizing multiple HIV strains, demonstrating broad responsiveness to newly spreading viruses, and enhancing protection against passive transfer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955699A_ABST
    Figure CN118955699A_ABST
Patent Text Reader

Abstract

The present invention relates to anti-HIV antibodies. Related methods and compositions are also disclosed. HIV causes acquired immunodeficiency syndrome (AIDS), i.e., a human condition characterized by clinical features including depletion syndrome, central nervous system degeneration, and leading to life-threatening opportunistic infections and malignant severe immunosuppression. Since it has been found in 1981, HIV type 1 (HIV-1) has resulted in death of at least 25,000,000 persons globally.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application based on a patent application with an application date of October 18, 2013, a priority date of October 18, 2012, an application number of 202110092787.9, and an invention name of "Broadly neutralizing anti-HIV antibodies".

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority under 35 USC §119(e) to U.S. Provisional Application No. 61 / 715,642, filed on October 18, 2012, and is incorporated herein in its entirety.

[0004] Government interests

[0005] The invention disclosed herein was made at least in part with government support under Grant No. P01AI081677 from the National Institutes of Health. Accordingly, the U.S. Government has certain rights in this invention. Field of the Invention

[0006] The present invention relates to broad and potent antibodies against human immunodeficiency virus ("HIV"). Background of the Invention

[0008] HIV causes acquired immunodeficiency syndrome (AIDS), a human condition characterized by clinical features including a wasting syndrome, degeneration of the central nervous system, and severe immunosuppression leading to life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has caused at least 25 million deaths worldwide. It is predicted that 20-60 million people will be infected in the next two decades, even with a 2.5% annual decline in HIV infections. There is a need for therapeutic agents and methods for treating or inhibiting HIV infection.

[0009] Some HIV infected individuals show broadly neutralizing IgG antibodies in their serum. However, despite its potential significance in designing effective vaccines, little is known about the specificity and activity of these antibodies. In animal models, passive transfer of neutralizing antibodies can contribute to protection from viral attack. Neutralizing antibody responses can also be formed in HIV infected individuals, but the detailed composition of hematological responses will also be fully revealed. SUMMARY OF THE INVENTION

[0011] The present invention relates to a novel class of broadly neutralizing anti-HIV antibodies. The consensus heavy and light chain amino acid sequences of the antibodies are listed below and are Figure 3 a and 3b show:

[0012]

[0013] In the sequence of SEQ ID NO: 1 or 2, each "X" can be any amino acid residue or no amino acid. Preferably, each X can be Figure 3 Residues at corresponding positions of the clonal variants 10-259, 10-303, 10-410, 10-847, 10-996, 10-1074, 10-1121, 10-1130, 10-1146, 10-1341, and 10-1369 shown in a and 3b, and the artificially modified form of the 10-1074 antibody 10-1074GM.

[0014] Thus, one aspect of the invention features an isolated anti-HIV antibody, or antigen-binding portion thereof, having at least one complementarity determining region (CDR) having a sequence selected from the group consisting of SEQ ID NOs: 33-38, with the proviso that the antibody is not antibody PGT-121, 122, or 123. SEQ ID NOs: 33-38 refer to the sequences of heavy chain CDRs (CDRH) 1-3 and light chain CDRs (CDRL) 1-3 under the Kabat system, e.g. Figure 3 a and 3b. In one embodiment, the CDR may contain a sequence selected from the group consisting of SEQ ID NOs: 39-104, i.e., CDR sequences under the KABAT system, as shown in Table 1 below. Alternatively, the CDR may contain a sequence selected from the group consisting of those corresponding antibody CDR sequences under the IMGT system, as shown in Table 1 below.

[0015] In one embodiment, the isolated anti-HIV antibody or antigen binding portion thereof comprises a heavy chain variable region comprising CDRH 1, CDRH 2, and CDRH 3, wherein CDRH 1, CDRH 2, and CDRH 3 comprise the corresponding sequences of SEQ ID NOs: 33-35. CDRH 1, CDRH 2, and CDRH 3 may also comprise the corresponding sequences of a CDRH group selected from the group consisting of SEQ ID NOs: 39-41, SEQ ID NOs: 45-47, SEQ ID NOs: 51-53, SEQ ID NOs: 57-59, SEQ ID NOs: 63-65, SEQ ID NOs: 69-71, SEQ ID NOs: 75-77, SEQ ID NOs: 81-83, SEQ ID NOs: 87-89, SEQ ID NOs: 93-95, SEQ ID NOs: 99-101, and SEQ ID NOs: 131-133. Alternatively, the CDRH may comprise the corresponding sequences selected from those corresponding antibody CDR sequences under the IMGT system as shown in Table 1 below.

[0016] In another embodiment, the isolated anti-HIV antibody or antigen binding portion thereof comprises a light chain variable region comprising CDRL 1, CDRL 2 and CDRL 3, wherein CDRL 1, CDRL 2 and CDRL 3 comprise the corresponding sequences of SEQ ID NOs: 36-38. For example, CDRL 1, CDRL 2 and CDRL 3 may comprise the corresponding sequences of a CDRL group selected from the group consisting of SEQ ID NOs: 42-44, SEQ ID NOs: 48-50, SEQ ID NOs: 54-56, SEQ ID NOs: 60-62, SEQ ID NOs: 66-68, SEQ ID NOs: 72-74, SEQ ID NOs: 78-80, SEQ ID NOs: 84-86, SEQ ID NOs: 90-92, SEQ ID NOs: 96-98, SEQ ID NOs: 102-104, and SEQ ID NOs: 134-136. Alternatively, the CDRLs may comprise the corresponding sequences selected from those corresponding antibody CDR sequences under the IMGT system as shown in Table 1 below.

[0017] In yet another embodiment, the above-mentioned isolated anti-HIV antibody or antigen-binding portion thereof comprises (i) a heavy chain variable region comprising CDRH 1, CDRH 2, and CDRH 3, and (ii) a light chain variable region comprising CDRL 1, CDRL 2, and CDRL 3. CDRH 1, CDRH 2, CDRH 3, CDRL 1, CDRL 2, and CDRL 3 may comprise the corresponding sequence of a CDR group selected from the group consisting of SEQ ID NO: 39-44, SEQ ID NO: 45-50, SEQ ID NO: 51-56, SEQ ID NO: 57-62, SEQ ID NO: 63-68, SEQ ID NO: 69-74, SEQ ID NO: 75-79, SEQ ID NO: 81-86, SEQ ID NO: 87-92, SEQ ID NO: 93-98, SEQ ID NO: 99-104, and SEQ ID NO: 131-136. Alternatively, CDRH and CDRL may contain corresponding sequences selected from those corresponding antibody CDR sequences under the IMGT system as shown in Table 1 below.

[0018] In a further embodiment, the isolated anti-HIV antibody or antigen binding portion thereof comprises one or both of the following: (i) a heavy chain having a consensus amino acid sequence of SEQ ID NO: 1 and (ii) a light chain having a consensus amino acid sequence of SEQ ID NO: 2. The heavy chain may contain a sequence selected from the group consisting of SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 129, and the light chain may contain a sequence selected from the group consisting of SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 130. For example, the heavy and light chains can comprise the corresponding sequences of SEQ ID NOs: 3-4, SEQ ID NOs: 5-6, SEQ ID NOs: 7-8, SEQ ID NOs: 9-10, SEQ ID NOs: 11-12, SEQ ID NOs: 13-14, SEQ ID NOs: 15-16, SEQ ID NOs: 17-18, SEQ ID NOs: 19-20, SEQ ID NOs: 21-22, SEQ ID NOs: 23-24, and 129-130.

[0019] In a preferred embodiment, the isolated anti-HIV antibody is an antibody selected from the group consisting of 10-259, 10-303, 10-410, 10-847, 10-996, 10-1074, 10-1074GM, 10-1121, 10-1130, 10-1146, 10-1341, and 10-1369. Figure 3 The corresponding heavy chain variable region, light chain variable region, CDRH 1-3 and CDRL 1-3 are shown in 3a and 3b. In a more preferred embodiment, the isolated anti-HIV antibody is a 10-1074-like antibody, i.e., an antibody selected from the group consisting of 10-847, 10-996, 10-1074, 10-1074GM, 10-1146, and 10-1341. The antibodies in this group are more potent than PGT121 in neutralizing contemporary viruses. The antibodies discussed above can be human antibodies, humanized antibodies, or chimeric antibodies.

[0020] In a second aspect, the invention provides an isolated nucleic acid having a sequence encoding a CDR, a heavy chain variable region, or a light chain variable region of an anti-HIV antibody or antigen binding portion thereof discussed above. Also featured are vectors having the nucleic acid and cultured cells having the vector.

[0021] Nucleic acids, vectors and cultured cells can be used in methods for producing anti-HIV antibodies or fragments thereof. The method particularly comprises the following steps: obtaining the cultured cells mentioned above; culturing the cells in a culture medium under conditions that allow expression of a polypeptide encoded by the vector and assembly of antibodies or fragments thereof, and purifying the antibodies or fragments from the cultured cells or the culture medium of the cells.

[0022] In a third aspect, the invention features a pharmaceutical composition containing (i) at least one anti-HIV antibody, or an antigen-binding portion thereof, as mentioned above, and (ii) a pharmaceutically acceptable carrier.

[0023] In a fourth aspect, the present invention provides a method for preventing or treating HIV infection or HIV-related diseases. The method comprises the following steps: identifying a patient in need of such prevention or treatment, and administering to the patient a first therapeutic agent comprising a therapeutically effective amount of at least one of the above-mentioned anti-HIV antibodies or antigen-binding fragments thereof. The method may further comprise administering a second therapeutic agent, such as an antiviral agent.

[0024] In a fifth aspect, the present invention provides a kit having a pharmaceutically effective amount of at least one of the above-mentioned isolated anti-HIV antibodies or antigen-binding portions thereof in a pharmaceutically acceptable dosage unit, and a pharmaceutically effective amount of an anti-HIV agent in a pharmaceutically acceptable dosage unit. The two pharmaceutically acceptable dosage units can optionally be in the form of a single pharmaceutically acceptable dosage unit. Exemplary anti-HIV agents can be selected from the group consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, entry or fusion inhibitors, and integrase inhibitors.

[0025] In a sixth aspect, the present invention provides a kit for diagnosis, prognosis or treatment monitoring of HIV infection in a subject. The kit contains one or more detection reagents that specifically bind to anti-HIV neutralizing antibodies in a biological sample from the subject. The kit may further include reagents for performing PCR or mass spectrometry.

[0026] The details of one or more embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description and from the claims.

[0027] The present disclosure includes the following embodiments:

[0028] Embodiment 1. An isolated anti-HIV antibody, or antigen-binding portion thereof, comprising at least one complementarity determining region (CDR) having a sequence selected from the group consisting of SEQ ID NOs: 33-38.

[0029] Embodiment 2. The isolated anti-HIV antibody or antigen-binding portion thereof of embodiment 1, wherein the CDR comprises a sequence selected from the group consisting of SEQ ID NOs: 39-104.

[0030] Embodiment 3. The isolated anti-HIV antibody or antigen-binding portion thereof of embodiment 1, comprising a heavy chain variable region comprising CDRH1, CDRH 2, and CDRH 3, wherein said CDRH 1, CDRH 2, and CDRH 3 comprise the corresponding sequences of SEQ ID NOs: 33-35.

[0031] Embodiment 4. The isolated anti-HIV antibody or antigen-binding portion thereof of embodiment 3, wherein the CDRH 1, CDRH 2 and CDRH 3 comprise the corresponding sequences of a CDRH group selected from the group consisting of SEQ ID NOs: 39-41, SEQ ID NOs: 45-47, SEQ ID NOs: 51-53, SEQ ID NOs: 57-59, SEQ ID NOs: 63-65, SEQ ID NOs: 69-71, SEQ ID NOs: 75-77, SEQ ID NOs: 81-83, SEQ ID NOs: 87-89, SEQ ID NOs: 93-95, SEQ ID NOs: 99-101, and SEQ ID NOs: 131-133.

[0032] Embodiment 5. The isolated anti-HIV antibody or antigen-binding portion thereof of embodiment 1, comprising a light chain variable region comprising CDRL1, CDRL 2 and CDRL 3, wherein said CDRL 1, CDRL 2 and CDRL 3 comprise the corresponding sequences of SEQ ID NOs: 36-38.

[0033] Embodiment 6. The isolated anti-HIV antibody or antigen-binding portion thereof of embodiment 5, wherein the CDRL 1, CDRL 2 and CDRL 3 comprise corresponding sequences of a CDRL group selected from the group consisting of SEQ ID NOs: 42-44, SEQ ID NOs: 48-50, SEQ ID NOs: 54-56, SEQ ID NOs: 60-62, SEQ ID NOs: 66-68, SEQ ID NOs: 72-74, SEQ ID NOs: 78-80, SEQ ID NOs: 84-86, SEQ ID NOs: 90-92, SEQ ID NOs: 96-98, SEQ ID NOs: 102-104, and SEQ ID NOs: 134-136.

[0034] Embodiment 7. The isolated anti-HIV antibody or antigen-binding portion thereof of embodiment 1, comprising a heavy chain variable region comprising CDRH1, CDRH 2, and CDRH 3, and

[0035] The light chain variable region comprises CDRL 1, CDRL 2 and CDRL 3.

[0036] Embodiment 8. The isolated anti-HIV antibody or antigen-binding portion thereof of embodiment 7, wherein the CDRH 1, CDRH 2, CDRH 3, CDRL 1, CDRL 2 and CDRL 3 comprise corresponding sequences of a CDR group selected from the group consisting of SEQ ID NOs: 39-44, SEQ ID NOs: 45-50, SEQ ID NOs: 51-56, SEQ ID NOs: 57-62, SEQ ID NOs: 63-68, SEQ ID NOs: 69-74, SEQ ID NOs: 75-79, SEQ ID NOs: 81-86, SEQ ID NOs: 87-92, SEQ ID NOs: 93-98, SEQ ID NOs: 99-104, and SEQ ID NOs: 131-136.

[0037] Embodiment 9. The isolated anti-HIV antibody or antigen-binding portion thereof of embodiment 1, comprising one or both of the following: (i) a heavy chain comprising the consensus amino acid sequence of SEQ ID NO: 1 and (ii) a light chain comprising the consensus amino acid sequence of SEQ ID NO: 2.

[0038] Embodiment 10. The isolated anti-HIV antibody or antigen-binding portion thereof of embodiment 9, wherein the heavy chain comprises a sequence selected from the group consisting of SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 129, and the light chain comprises a sequence selected from the group consisting of SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 130.

[0039] Embodiment 11. The isolated anti-HIV antibody or antigen-binding portion thereof of Embodiment 9, wherein the heavy chain and the light chain comprise the corresponding sequences of SEQ ID NOs: 3-4, SEQ ID NOs: 5-6, SEQ ID NOs: 7-8, SEQ ID NOs: 9-10, SEQ ID NOs: 11-12, SEQ ID NOs: 13-14, SEQ ID NOs: 15-16, SEQ ID NOs: 17-18, SEQ ID NOs: 19-20, SEQ ID NOs: 21-22, SEQ ID NOs: 23-24, and 129-130.

[0040] Embodiment 12. The isolated anti-HIV antibody or antigen binding portion thereof of embodiment 1, wherein the antibody is an antibody selected from the group consisting of 10-259, 10-303, 10-410, 10-847, 10-996, 10-1074, 10-1121, 10-1130, 10-1146, 10-1341, 10-1369, and 10-1074GM.

[0041] Embodiment 13. The isolated anti-HIV antibody, or antigen-binding portion thereof, of any one of embodiments 1-12, wherein the antibody is a human antibody, a humanized antibody, or a chimeric antibody.

[0042] Embodiment 14. An isolated nucleic acid comprising a sequence encoding the CDR, heavy chain variable region, or light chain variable region of the anti-HIV antibody or antigen-binding fragment thereof of any one of embodiments 1-13.

[0043] Embodiment 15. A vector comprising the nucleic acid of embodiment 14.

[0044] Embodiment 16. A cultured cell comprising the vector of embodiment 15.

[0045] Embodiment 17. A pharmaceutical composition comprising (i) at least one anti-HIV antibody or antigen-binding fragment thereof according to any one of embodiments 1-13, and (ii) a pharmaceutically acceptable carrier.

[0046] Embodiment 18. A method for preventing or treating HIV infection or HIV-related diseases, comprising the following steps:

[0047] Identify patients in need of such prevention or treatment, and

[0048] A first therapeutic agent comprising a therapeutically effective amount of at least one anti-HIV antibody or antigen-binding fragment thereof according to any one of embodiments 1-13 is administered to the patient.

[0049] Embodiment 19. The method of embodiment 18, further comprising administering a second therapeutic agent.

[0050] Embodiment 20. The method of embodiment 19, wherein the second therapeutic agent is an antiviral agent.

[0051] Embodiment 21. A method for producing an anti-HIV antibody or fragment thereof, comprising

[0052] Obtaining the cultured cells of embodiment 16;

[0053] culturing the cells in a culture medium under conditions that allow expression of the polypeptide encoded by the vector and assembly of the antibody or fragment thereof, and

[0054] The antibody or fragment is purified from the cultured cells or the culture medium of the cells.

[0055] Embodiment 22. A kit comprising:

[0056] a pharmaceutically effective amount of at least one isolated anti-HIV antibody according to any one of embodiments 1 to 13 in a pharmaceutically acceptable dosage unit, and

[0057] a pharmaceutically effective amount of an anti-HIV agent in a pharmaceutically acceptable dosage unit,

[0058] Two of the pharmaceutically acceptable dosage units may optionally be combined into a single pharmaceutically acceptable dosage unit.

[0059] Embodiment 23. The kit of embodiment 22, wherein the anti-HIV agent is an anti-HIV agent selected from the group consisting of a non-nucleoside reverse transcriptase inhibitor, a protease inhibitor, an entry or fusion inhibitor, and an integrase inhibitor.

[0060] Embodiment 24. A kit for diagnosis, prognosis or treatment monitoring of HIV infection in a subject, comprising one or more detection reagents that specifically bind to anti-HIV neutralizing antibodies in a biological sample from the subject.

[0061] Embodiment 25. The kit of embodiment 24, further comprising reagents for performing PCR.

[0062] Embodiment 26. The kit of embodiment 25, further comprising reagents for performing mass spectrometry.

[0063] The present disclosure further includes the following embodiments: Embodiment 1. An isolated bispecific anti-HIV antibody or antigen-binding portion thereof comprising a first antigen-binding arm and a second antigen-binding arm,

[0064] wherein the first antigen binding arm and the second antigen binding arm specifically bind to different epitopes or molecules,

[0065] Wherein the first antigen binding arm comprises CDRH 1, CDRH 2, CDRH 3, CDRL 1, CDRL 2, and CDRL3, wherein the CDRH 1, CDRH 2, CDRH 3, CDRL 1, CDRL 2, and CDRL 3 comprise corresponding sequences of a CDR group selected from the group consisting of SEQ ID NOs: 69-74, SEQ ID NOs: 57-62, SEQ ID NOs: 63-68, SEQ ID NOs: 87-92, and SEQ ID NOs: 93-98.

[0066] Embodiment 2. The isolated bispecific anti-HIV antibody or antigen-binding portion thereof of Embodiment 1, comprising a heavy chain variable region and a light chain variable region having the corresponding sequences shown in SEQ ID NOs: 13-14, SEQ ID NOs: 9-10, SEQ ID NOs: 11-12, SEQ ID NOs: 19-20 or SEQ ID NOs: 21-22.

[0067] Embodiment 3. The isolated bispecific anti-HIV antibody or antigen-binding portion thereof of embodiment 1 or 2, comprising a heavy chain and a light chain having the corresponding sequences shown in SEQ ID NOs: 13-14, SEQ ID NOs: 9-10, SEQ ID NOs: 11-12, SEQ ID NOs: 19-20 or SEQ ID NOs: 21-22.

[0068] Embodiment 4. The isolated bispecific anti-HIV antibody or antigen-binding portion thereof of Embodiment 1, wherein said CDRH 1, CDRH 2, CDRH 3, CDRL 1, CDRL 2 and CDRL 3 comprise the corresponding sequences of SEQ ID NOs: 69-74.

[0069] Embodiment 5. The isolated bispecific anti-HIV antibody or antigen binding portion thereof of embodiment 1, comprising a heavy chain variable region and a light chain variable region having the corresponding sequences of SEQ ID NOs: 13-14.

[0070] Embodiment 6. The isolated bispecific anti-HIV antibody or antigen binding portion thereof of embodiment 5, comprising a heavy chain and a light chain having the corresponding sequences of SEQ ID NOs: 13-14.

[0071] Embodiment 7. The isolated bispecific anti-HIV antibody, or antigen binding portion thereof, of any one of Embodiments 1-6, wherein the second antigen binding arm binds a trigger molecule on a leukocyte.

[0072] Embodiment 8. The isolated bispecific anti-HIV antibody, or antigen binding portion thereof, of any one of Embodiments 1-7, wherein the second antigen binding arm binds a T cell receptor molecule.

[0073] Embodiment 9. The isolated bispecific anti-HIV antibody, or antigen binding portion thereof, of any one of embodiments 1-8, wherein the second antigen binding arm binds CD3.

[0074] Embodiment 10. The isolated bispecific anti-HIV antibody, or antigen-binding portion thereof, of any one of embodiments 1-9, wherein the antibody is a human antibody, a humanized antibody, or a chimeric antibody.

[0075] Embodiment 11. The isolated bispecific anti-HIV antibody or antigen binding portion thereof of any one of embodiments 1-2, 4-5 and 7-9, wherein the first antigen binding arm is selected from the group consisting of Fab, F(ab')2, Fv and scFv.

[0076] Embodiment 12. An isolated nucleic acid comprising a sequence encoding the bispecific anti-HIV antibody, or antigen-binding portion thereof, of any one of embodiments 1-11.

[0077] Embodiment 13. A vector comprising the nucleic acid of embodiment 12.

[0078] Embodiment 14. A cultured cell comprising the nucleic acid of embodiment 12 or the vector of embodiment 13.

[0079] Embodiment 15. A pharmaceutical composition comprising

[0080] (i) at least one anti-HIV antibody or antigen-binding portion thereof according to any one of embodiments 1 to 11, or a nucleic acid according to embodiment 12, or a vector according to embodiment 13, or a cultured cell according to embodiment 14, and

[0081] (ii) a pharmaceutically acceptable carrier.

[0082] Embodiment 16. The pharmaceutical composition of Embodiment 15, further comprising a second therapeutic agent.

[0083] Embodiment 17. The pharmaceutical composition of embodiment 16, wherein the second therapeutic agent comprises an antiviral agent or a second anti-HIV antibody or antigen-binding portion thereof.

[0084] Embodiment 18. A method of preventing or treating HIV infection or HIV-related disease in a patient, comprising administering to the patient a therapeutic agent comprising a therapeutically effective amount of an anti-HIV antibody or antigen-binding portion thereof according to any one of embodiments 1-11.

[0085] Embodiment 19. The method of embodiment 18, further comprising administering a second therapeutic agent.

[0086] Embodiment 20. The method of embodiment 19, further comprising administering an antiviral agent.

[0087] Embodiment 21. Use of at least one anti-HIV antibody or antigen-binding portion thereof according to any one of embodiments 1 to 11, or the nucleic acid according to embodiment 12, or the vector according to embodiment 13, or the cultured cell according to embodiment 14 for preventing or treating HIV infection.

[0088] Embodiment 22. A method for producing an anti-HIV antibody or fragment thereof, comprising

[0089] Obtaining the cultured cells of embodiment 14;

[0090] culturing the cells in a culture medium under conditions that allow expression of the polypeptide encoded by the vector and assembly of the antibody or fragment thereof, and

[0091] The antibody or fragment is purified from the cultured cells or the culture medium of the cells.

[0092] Embodiment 23. A kit comprising:

[0093] A pharmaceutically effective amount of at least one isolated anti-HIV antibody according to any one of embodiments 1-11, or a nucleic acid according to embodiment 12, or a vector according to embodiment 13, or a cultured cell according to embodiment 14 in a pharmaceutically acceptable dosage unit.

[0094] Embodiment 24. The kit of embodiment 23, further comprising a pharmaceutically effective amount of an anti-HIV agent in pharmaceutically acceptable dosage units, wherein the two pharmaceutically acceptable dosage units may optionally be in the form of a single pharmaceutically acceptable dosage unit. BRIEF DESCRIPTION OF THE DRAWINGS

[0096] Figure 1 Shown: Neutralizing activity of PGT121-like and 10-1074-like variants. (A) Heat map comparing the neutralizing potency of PGT121-like and 10-1074-like antibodies in the TZM-b1 assay. Darker colors = more potent neutralization; white = no neutralization. (B) Mean IC against 9 viruses 80 (y-axis) and the apparent K for binding to gp120 and gp140 D (C) Comparison of the neutralization breadth and potency of PGT121, 10-996 and 10-1074 antibodies in the TZM-b1 assay against an expanded panel of 119 viruses. The y-axis shows the IC up to the concentration shown on the x-axis. 50 The spider plot (upper left) shows the frequency distribution of neutralized viruses according to HIV-1 clade. (D) Molar neutralization ratios (MNR; IC values ​​for Fab and IgG) are shown. 50 The horizontal bar represents the mean IC value of all viruses. 50 (E) Bar graph comparing the neutralization potency of PGT121 (dark grey) and 10-1074 (light grey) against viruses isolated from historical (Hist.) and contemporary (Cont.) seroconverters. ns, not significant; **, p<0.005. The median IC values ​​of PGT121 and 10-1074 for neutralization of contemporary viruses are indicated. 50 The multiple difference between .

[0097] Figure 2 Display: PGT121 GM and 10-1074 GM Binding and neutralizing activities of mutant antibodies. (A) Comparison of 10-1074, PGT121, and PGT121 GM and 10-1074 GM Apparent K of antibody binding to gp120 and gp140 D The error bars indicate the K values ​​obtained from three independent experiments. D The SEM of the values. The K values ​​of the "wild type" and "glycomutant" antibodies are indicated. D (B) Compared with mutant antibody (PGT121 GM and 10-1074 GM ) Comparison of PGT121 and 10-1074 on glycans ( Figure 7 A) Histogram of binding. Numerical scores for binding were measured as the fluorescence intensity of 5 fmol of probe arrayed per spot (mean across duplicate spots). (C) Comparison of PGT121, PGT121 in the TZM-b1 assay against a panel of 40 viruses. GM , 10-1074 and 10-1074 GM Overlay of neutralization breadth and potency of antibodies.

[0098] Figure 3 Depicted: Sequence alignment of PGT121 and 10-1074 clonal variants. (A) Amino acid alignment of the heavy chain (IgH) of PGT121-like and 10-1074-like antibodies, and possible germline (GL) VH of all clonal variants. Amino acid numbering based on crystal structure, framework (FWR) and complementarity determining region (CDR) is indicated, as defined by Kabat (. J Exp Med 132 (2): 211-250) and IMGT (Nucleic Acids Res 37 (Database issue): D1006-1012). Color shading shows acidic (red), basic (blue), tyrosine (green) amino acids. (B) Same as A, but for the light chain (IgL).

[0099] Figure 4 Shown: Binding affinities of PGT121 and 10-1074 clone variants. (A) Binding affinities of the interactions of PGT121 IgG antibody variants with YU-2 gp140 and gp120 ligands as measured by surface plasmon resonance (SPR). M, mol / 1; s, seconds; RU, response unit; / , no detectable binding. 2 Value (χ 2) <10 indicates that the 1:1 binding model used to fit the curves adequately describes the experimental data. The equilibrium and kinetic constants shown are considered to be "apparent" constants to account for the avidity effects derived from IgG bivalent binding. (B) Dot plot showing the binding (k) of PGT121-like (blue shading) and 10-1074-like (green shading) a ) and dissociation (k d ) Rate constant. (C) Linear regression plot comparing the k of IgG antibodies in terms of their binding to gp120 and gp140 a and k d The values ​​(x-axis) are the neutralization potency (mean IC 80 value)(y-axis).

[0100] Figure 5 Depicted: PGT121 variants affect gp120 "core" protein, gp120 GD324-5AA Mutant and linear gp120 V3 (A) ELISA-based binding of PGT121-like and 10-1074-like antibodies to HXB2 gp120 compared to intact YU-2 gp120. 核心 Binding analysis of 2CC-core protein. The x-axis shows the ELISA value (OD 405nm ) The antibody concentration (M) required. Anti-CD4bs antibody VRC01 (Science 329 (5993): 856-861), anti-V3 loop antibody 10-188 (PLoS One 6 (9): e24078), and non-HIV reactive antibody mGO53 (Science 301 (5638): 1374-1377) were used as controls. (B) Same as (A), except for gp120 binding GD324-5AA (c) Comparison of PGT121 and 10-1074-like antibodies and antibodies against gp120 V3-C3 Bar graph of ELISA reactivity of control antibodies to overlapping peptides (positive controls 10-188, 1-79, 2-59 and 2-1261 (Nature 458(7238): 636-640)), and negative control mGO53). The y-axis indicates the ELISA value (OD 405nm ). The amino acid sequence of each peptide is shown in the lower right. All experiments were performed at least in duplicate. Representative data are shown.

[0101] Figure 6Depicted: Binding of PGT121 to gp120 glycosylation mutants and deglycosylated gp120. (A) ELISA-based binding of PGT121 and 10-1074 antibody variants to gp120, gp120 NNT301-303AAA 、gp120 N332A and gp120 N332A / NNT301-303AAA The x-axis shows the ELISA value (OD 405nm ) Required antibody concentration (M). The black dashed and continuous lines show the average reactivity of positive (10-188) and negative (mGO53) antibody controls against the four antigens. (B) Silver-stained SDS-PAGE gel comparing untreated gpl20 (WT, wild type), gpl20s digested with PNGase F and EndoH. L, protein ladder. (C), same as (A), except comparing untreated and PNGase F-treated gpl20. (D) Same as (A), except comparing untreated and EndoH-treated gpl20. All experiments were performed at least in duplicate.

[0102] Figure 7 Depicted: Binding of glycans by PGT121 and 10-1074 clonal variants. (A) Monosaccharide sequences of a panel of 15 N-glycan probes used in glycan microarray analysis to examine direct binding to N-glycans for PGT121-like and 10-1074-like antibodies. DH refers to the lipid tag 1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine (DHPE) conjugated to N-glycans by reductive amination. The key features noted are that (i) the PGT121 group of antibodies binds to the monoantennary N-glycan probe 10 (N2) having antennae terminated with galactose linked to the core mannose via 1-3 linkages, while the non-isomer N-glycan probe 11 (referred to as N4) has antennae linked to the core mannose via 1-6 linkages; (ii) the presence of such 1-6-linked antennae terminated with galactose (as in the biantennary probe 13 (NA2)) allows binding, as does the presence of α2-6-linked (but not α2-3-linked) sialic acid; (iii) the biantennary probe 12 (NGA2) lacking galactose and terminated with N-acetylglucosamine is not bound. (B) Bar graph comparing glycan binding of PGT121-like, 10-1074-like, and germline form (GL) antibodies. 10-188 (an anti-V3 loop antibody) was used as a negative control. Numerical scores for binding were measured as fluorescence intensity (mean across duplicate spots) of probe arrayed at 2 fmol (white) and 5 fmol (grey) per spot.

[0103] Figure 8Depicted: Antibody binding and neutralizing activity against high mannose gp120 and virus only. (A) Comparison of antibody binding and neutralizing activity against high mannose gp120 and virus only. kif Silver-stained SDS-PAGE gel of YU-2gp120 produced in cells treated with PGT121 (blue marker) and gp120 produced in untreated cells (WT, wild type). L, protein ladder. (B) PGT121-like (blue marker) and 10-1074-like (green marker) antibodies against YU-2gp120 (gp120 WT ) and gp120 kif The x-axis shows the ELISA value (OD 405nm ) The antibody concentration (M) required. (C) Against the presence of (virus kif ) or lack thereof (Virus WT ) Neutralization curve of PGT121 generated in the case of kifunicine for evaluation of PGT121 sensitivity / 10-1074 resistance pseudoviruses. The horizontal dotted line indicates 50% neutralization, where IC 50 The values ​​can be derived from the antibody concentration on the x-axis. The experiment was performed in triplicate. The error bars indicate the SD of the triplicate measurements. (D) Comparison of the antibody concentration against HEK 293S GnTI - / - Cells (Viruses GnT - / - ) or in wild-type cells (virus WT ) are bar graphs showing the neutralization activity of selected antibodies against YU-2 and PVO.4 pseudoviruses generated in . The y-axis shows the mean IC values ​​for neutralization of the viruses shown on the x-axis. 50 Values ​​(μg / ml). Error bars indicate IC obtained from two independent experiments. 50 SEM of values.

[0104] Fig. 9 Shown: Neutralization activity of PGT121, 10-996 and 10-1074. (A) Comparison of the neutralization potency of PGT121, 10-996 and 10-74 against viruses of the indicated HIV-1 clades (assayed using the TZM-b1 assay and a panel of 119 pseudoviruses). The x-axis shows the antibody concentration (μg / ml) required to achieve 50% neutralization (IC 50 ). The y-axis shows the IC up to the concentration shown on the x-axis. 50 (B) Comparison of the neutralization breadth and potency of PGT121, 10-996, and 10-1074 antibodies against an expanded panel of 119 viruses, as determined by the TZM-b1 neutralization assay. The y-axis shows the IC up to the concentration shown on the x-axis. 80(C) The graph shows the neutralization curves of PGT121 and 10-1074 against selected viruses. The horizontal dotted line indicates 50% neutralization, where IC 50 Values ​​can be derived from the antibody concentration on the x-axis. Experiments were performed in triplicate. Error bars indicate SD of triplicate measurements.

[0105] Fig.10 Depicted: Neutralizing activity against historical vs. contemporary clade B viruses. Dot plot comparing the neutralizing potency of selected bNAbs against clade B viruses isolated from historical (Hist.) and contemporary (Cont.) seroconverters. Horizontal bars represent the median IC for all viruses per patient. 50 The Mann-Whitney test was used to assess differences between groups. ns, not significant.

[0106] Fig.11 Depicted: Neutralization of two R5-tropical SHIVs by a panel of 11 broadly active anti-HIV-1 mAbs. Calculated IC50 values ​​for neutralization of SHIVAD8EO (A) and SHIVDH12-V3AD8 (B).

[0107] Fig.12 Depicted: The relationship between plasma concentrations of passively administered neutralizing mAbs and viral acquisition in macaques following challenge with two different R5 SHIVs. Closed circles indicate protected (no acquisition) monkeys; open circles indicate infected animals.

[0108] Fig.13 Depicted: Plasma concentration of bNAbs. Concentrations of mAbs were determined by measuring neutralizing activity in plasma samples. (A) ID50 values ​​measured in the TZM.b1 neutralization assay against 10-1074 and 3BNC117 against HIV-1 strains sensitive to one but not another bNAb (i.e., HIV-1 strain X2088_9 (sensitive to 10-1074); HIV-1 strain Q769_d22 (sensitive to 3BNC117). (B) Neutralizing activity of plasma before antibody administration (preP), but spiked with 0.01, 0.1, 1, 10, and 100 μg / ml of antibody 10-1074 (blue) or 3BNC117 (green). Based on the measured ID50 values ​​in (A), the neutralization activity of plasma was measured. ID50 Titers (left column) are reported and neutralizing activity converted to antibody concentrations (right column). (C) Neutralization activity measured in indicated macaque plasma samples before (pre-bleeding) and after (days) bNAb administration ID50 Titer (left column) and bNAb concentration (right column). DETAILED DESCRIPTION OF THE INVENTION

[0110] The present invention is based, at least in part, on the unexpected discovery of a new class of broadly neutralizing antibodies (bNAbs) against HIV that recognize carbohydrate-dependent epitopes on gp120, including complex N-glycans.

[0111] Antibodies are essential for the success of most vaccines, and antibodies against HIV appear to be the only correlate of protection in the recent RV144 anti-HIV vaccine trial. Some HIV-1 infected patients develop broadly neutralizing serological activity against the gp160 viral spike 2-4 years after infection, but these antibodies generally do not protect infected humans due to autologous virus escape via mutation. However, broadly neutralizing activity exerts selection pressure on the virus, and passive transfer of broadly neutralizing antibodies (bNAbs) to macaques provides protection against SHIV infection. Therefore, it has been proposed that vaccines that elicit such antibodies may be protective against HIV infection in humans.

[0112] Development of single-cell antibody cloning technology revealed that bNAbs target several different epitopes on the HIV-1 gp160 spike. The most potent HIV-1 bNAbs recognize the CD4 binding site (CD4b) (Science 333 (6049): 1633-1637; Nature 477 (7365): 466-470; Science 334 (6060): 1289-1293) and the variable loops (Nature 477 (7365): 466-470; Science 326 (5950): 285-289; Science 334 (6059): 1097-1103; Nature 480 (7377): 336-343), including V1 / V2 (PG9 / PG16) (Science 326 (5950): 285-289) and V3 loop (PGT) (Nature 477(7365):466-470). Little is known about carbohydrate-dependent epitopes because the antibodies studied so far are unique examples or members of small clonal families.

[0113] To better understand the response of neutralizing antibodies to HIV-1 and epitopes targeted by PGT antibodies, we isolated members of a large clonal family that controls the gp160-specific IgG memory response from patients infected with clade A that generated PGT121. As disclosed herein, PGT121 antibodies are divided into two groups, PGT121-like and 10-1074-like groups, based on sequence, binding affinity, neutralizing activity and recognition of carbohydrates and V3 loops. 10-1074 and related family members exhibit rare and potent neutralization, including broad reactivity against newly transmitted viruses. Unlike previously characterized carbohydrate-dependent bNAbs, PGT121 binds to complex, rather than high-mannose N-glycans in glycan microarray experiments. The crystal structures of PGT121 and 10-1074 compared to the structures of their germline precursors and the PGT121 structure bound to complex N-glycans rationalize their unique properties.

[0114] In one example, an assay was performed to isolate B cell clones encoding PGT121, which is unique among glycan-dependent bNAbs in recognizing complex, rather than high mannose N-glycans. PGT121 clones were divided into PGT121 and 10-1074-like groups distinguished by sequence, binding affinity, carbohydrate recognition, and neutralizing activity. The 10-1074 group exhibited significant potency and breadth, despite undetectable binding to protein-free glycans. Crystal structures of ligand-free PGT121, 10-1074, and their germline precursors revealed that differential carbohydrate recognition localized to a cleft between CDRH2 and CDRH3, which was occupied by complex N-glycans in the separated PGT121 structure. The exchanged glycan contact residues between PGT121 and 10-1074 confirmed the significance of these residues in neutralizing activity. The HIV envelope exhibits variable ratios of high mannose and complex N-glycans, so these results, including the first structural characterization of complex N-glycan recognition by anti-HIV bNAbs, are critical for understanding how antibodies and ultimately vaccines can achieve broadly neutralizing activity.

[0115] As used herein, the term "antibody" (Ab) includes monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies and multireactive antibodies), and antibody fragments. Thus, as used in any context within this specification, the term "antibody" is intended to include, but is not limited to, any specific binding member, immunoglobulin class and / or isotype (e.g., IgG1, IgG2, IgG3, IgG4, IgM, IgA, IgD, IgE, and IgM); and its biologically relevant fragments or specific binding members, including but not limited to Fab, F(ab')2, Fv, and scFv (single chain or related entities). It should be understood in the art that an antibody is a glycoprotein or antigen binding portion thereof having at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. The heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH1, CH2, and CH3). The light chain consists of a light chain variable region (VL) and a light chain constant region (CL). The variable regions of both heavy and light chains contain framework regions (FWRs) and complementarity determining regions (CDRs). The four FWR regions are relatively conservative, while the CDR regions (CDR1, CDR2, and CDR3) represent hypervariable regions and are arranged from the NH2 end to the COOH end as follows: FWR1, CDR1, FWR2, CDR2, FWR3, CDR3, and FWR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens, while the constant regions can mediate the binding of immunoglobulins to host tissues or factors, depending on the isotype.

[0116] As used herein, also included within the definition of "antibody" are chimeric antibodies, humanized antibodies, and recombinant antibodies, human antibodies produced from transgenic non-human animals, and antibodies selected from libraries using enrichment techniques available to the skilled artisan.

[0117] The term "variable" refers to the fact that certain segments of the variable (V) domains are widely different in sequence between antibodies. The V domain mediates antigen binding and defines the specificity of a particular antibody to its specific antigen. However, variability is not evenly distributed across the span of 110 amino acids in the variable region. Instead, the V region is composed of relatively constant segments of 15-30 amino acids called framework regions (FRs) separated by shorter regions of extreme variability called "hypervariable regions" of 9-12 amino acids each. The variable regions of native heavy and light chains each comprise 4 FRs (mainly using beta folding structures) connected by 3 hypervariable regions (which form loops connected and in some cases form part of a beta folding structure). The hypervariable regions in each chain are held together in extreme proximity by the FRs and, together with the hypervariable regions from the other chain, contribute to the formation of the antibody antigen-binding site (see, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)).

[0118] As used herein, the term "hypervariable region" refers to the amino acid residues of an antibody that are responsible for antigen binding. A hypervariable region generally comprises amino acid residues from a "complementarity determining region" ("CDR").

[0119] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous antibody population, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. The term "polyclonal antibody" refers to a preparation comprising different antibodies directed against a determinant ("epitope").

[0120] The monoclonal antibodies herein include "chimeric" antibodies (in which a portion of the heavy chain and / or light chain is identical or homologous to the corresponding sequence in an antibody derived from a particular species or belonging to a particular antibody class or subclass, and the remainder of each chain is identical or homologous to the corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass) and fragments of such antibodies, as long as they exhibit the desired biological activity (see, e.g., U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81: 6851-6855 (1984)). The described invention provides variable region antigen-binding sequences derived from human antibodies. Thus, the chimeric antibodies of primary interest herein include antibodies having one or more human antigen-binding sequences (e.g., CDRs) and containing one or more sequences derived from non-human antibodies (e.g., FR or C region sequences). In addition, chimeric antibodies included herein are those that comprise a human variable region antigen-binding sequence of one antibody class or subclass and another sequence (eg, FR or C region sequence) derived from another antibody class or subclass.

[0121] A "humanized antibody" is generally considered to be a human antibody that has one or more amino acid residues from a non-human source introduced into it. These non-human amino acid residues are often referred to as "import" residues, which are generally taken from an "import" variable region. Humanization can be performed following the method of Winter and coworkers (see, e.g., Jones et al., Nature, 321: 522-525 (1986); Reichmann et al., Nature, 332: 323-327 (1988); Verhoeyen et al., Science, 239: 1534-1536 (1988)), which is performed by replacing the corresponding sequences of a human antibody with the sequences of the imported variable region. Thus, such "humanized" antibodies are chimeric antibodies (see, e.g., U.S. Patent No. 4,816,567), in which substantially less than the entire human variable region has been replaced with the corresponding sequence from a non-human species.

[0122] "Antibody fragments" comprise a portion of an intact antibody, such as the antigen binding or variable region of an intact antibody. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies (see, e.g., U.S. Pat. No. 5,641,870; Zapata et al., Protein Eng. 8(10): 1057-1062

[1995] ); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

[0123] "Fv" is a minimal antibody fragment containing a complete antigen recognition and antigen binding site. This fragment contains a dimer of a heavy chain variable region and a light chain variable region in tight non-covalent association. From the folding of these two domains, 6 hypervariable loops (3 loops each from H and L chains) are derived, which contribute amino acid residues to antigen binding and confer antigen binding specificity to the antibody. However, even a single variable region (or half of an Fv containing only 3 CDRs specific for an antigen)) has the ability to recognize and bind antigens, although with a lower affinity than a complete binding site.

[0124] "Single-chain Fv" ("sFv" or "scFv") is an antibody fragment comprising VH and VL antibody domains linked into a single polypeptide chain. The sFv polypeptide may further comprise a polypeptide linker between the VH and VL domains that enables the sFv to form the desired structure for antigen binding. For a review of sFv, see, e.g., Pluckthun in The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore, eds., Springer-Verlag, New York, pp. 269-315 (1994); Borrebaeck 1995, see below.

[0125] The term "diabody" refers to small antibody fragments prepared by constructing sFv with a short linker (about 5-10 residues) between the VH and VL domains, thereby achieving interchain rather than intrachain pairing of the V domains, generating a bivalent fragment (i.e., a fragment with two antigen binding sites). Bispecific diabodies are heterodimers of two "crossover" sFv fragments, in which the VH and VL domains of the two antibodies are present on different polypeptide chains. Diabodies are more fully described in, for example, EP 404,097; WO 93 / 11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90: 6444-6448 (1993).

[0126] Domain antibodies (dAb) (which can be generated in fully human form) are the smallest known antigen-binding fragments of antibodies, ranging from about 11kDa to about 15kDa. dAb is the robust variable region of the heavy chain and light chain (VH and VL, respectively) of immunoglobulin. They are highly expressed in microbial cell cultures, show favorable biophysical properties, including, for example, but not limited to solubility and temperature stability, and are fully suitable for selection and affinity maturation by in vitro selection systems such as, for example, phage display. dAb is biologically active as a monomer, and due to its smaller size and intrinsic stability, can be arranged into larger molecules to create a drug with extended serum half-life or other pharmacological activity. The example of this technology has been recorded in, for example, WO9425591 (about antibodies derived from Camelidae (Camelidae) heavy chain Ig) and US20030130496 (it describes the separation of single domain fully human antibodies from phage libraries).

[0127] Fv and sFv are the only species with complete combining sites lacking constant regions. In this way, they are suitable for reduced non-specific binding during in vivo use. sFv fusion proteins can be constructed as fusions of effector proteins produced at the amino or carboxyl termini of sFv. See, for example, Antibody Engineering, Borrebaeck, ed., supra. Antibody fragments can also be "linear antibodies", such as those described in, for example, U.S. Patent No. 5,641,870. Such linear antibody fragments can be monospecific or bispecific.

[0128] In certain embodiments, the antibodies of the invention described are bispecific or multispecific. Bispecific antibodies are antibodies that have binding specificity to at least two different epitopes. Exemplary bispecific antibodies can bind to two different epitopes of a single antigen. Other such antibodies can combine the binding sites of the first antigen binding site and the second antigen. Alternatively, the anti-HIV arm can be combined with the following arm, which binds to trigger molecules on target cells, such as T cell receptor molecules (e.g., CD3), or IgG Fc receptors (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16), so as to focus and localize the cell defense mechanism to infected cells. Bispecific antibodies can also be used to localize cytotoxic agents to infected cells. Bispecific antibodies can be prepared with full-length antibodies or antibody fragments (e.g., F(ab')2 bispecific antibodies). For example, WO 96 / 16673 describes a bispecific anti-ErbB2 / anti-FcγRIII antibody, and U.S. Pat. No. 5,837,234 discloses a bispecific anti-ErbB2 / anti-FcγRI antibody. For example, WO 98 / 02463 reports a bispecific anti-ErbB2 / Fcα antibody; U.S. Pat. No. 5,821,337 teaches a bispecific anti-ErbB2 / anti-CD3 antibody. See also, for example, Mouquet et al., Polyreactivity Increases The Apparent Affinity Of Anti-HIV Antibodies By Heteroligation. Nature. 467, 591-5 (2010), and Mouquet et al., Enhanced HIV-1 neutralization by antibody heteroligation "Proc Natl Acad Sci US A. 2012 Jan 17; 109 (3): 875-80.

[0129] Methods for generating bispecific antibodies are known in the art. The traditional generation of full-length bispecific antibodies is based on the co-expression of two immunoglobulin heavy chain-light chain pairs, wherein the two chains have different specificities (see, e.g., Millstein et al., Nature, 305: 537-539 (1983)). Similar procedures are disclosed in, e.g., WO 93 / 08829, Traunecker et al., EMBO J., 10: 3655-3659 (1991), and also see Mouquet et al., Enhanced HIV-1neutralization by antibody heteroligation "Proc Natl Acad Sci US A. 2012 Jan 17; 109 (3): 875-80.

[0130] Alternatively, the antibody variable region (antibody-antigen combination site) with the desired binding specificity can be fused with the immunoglobulin constant domain sequence. The fusion has an Ig heavy chain constant domain, which includes at least a portion of the hinge, CH2, and CH3 regions. According to some embodiments, the first heavy chain constant region (CH1) containing the site necessary for light chain bonding is present in at least one fusion. The DNA encoding the immunoglobulin heavy chain fusion and (if desired) immunoglobulin light chain is inserted into different expression vectors and co-transfected into a suitable host cell. This provides greater flexibility in adjusting the mutual ratio of the three polypeptide fragments in the embodiment when the different ratios of the three polypeptide chains used in the construction provide the optimal yield of the desired bispecific antibody. However, it is possible to insert the coding sequence of two or all three polypeptide chains into a single expression vector when the expression of at least two polypeptide chains of equal ratios results in high yield or when the ratio has no significant effect on the yield of the desired chain combination.

[0131] The technology for generating bispecific antibodies from antibody fragments has also been documented in the literature. For example, chemical linkage can be used to prepare bispecific antibodies. For example, Brennan et al., Science, 229: 81 (1985) describes a procedure in which proteolytic cleavage of intact antibodies generates F(ab')2 fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize adjacent dithiols and prevent intermolecular disulfide formation. Then, the generated Fab' fragments are converted into thionitrobenzoate (TNB) derivatives. Then, one of the Fab'-TNB derivatives is converted back into Fab'-thiol by reduction with mercaptoethylamine, and mixed with another Fab'-TNB derivative in equimolar amounts to form a bispecific antibody. The generated bispecific antibodies can be used as agents for selectively immobilized enzymes.

[0132] Other modifications of antibodies are contemplated herein. For example, the antibody can be linked to one of a variety of nonproteinaceous polymers (e.g., polyethylene glycol, polypropylene glycol, polyoxyalkylene, or copolymers of polyethylene glycol and polypropylene glycol). The antibody can also be encapsulated in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (e.g., hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules, respectively), in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or in macroemulsions. Such techniques are disclosed, for example, in Remington's Pharmaceutical Sciences, 16th edition, Oslo, A., ed., (1980).

[0133] Typically, the antibodies of the described invention are produced recombinantly using vectors and methods available in the art. Human antibodies can also be produced by in vitro activated B cells (see, e.g., U.S. Pat. Nos. 5,567,610 and 5,229,275). General methods of molecular genetics and genetic engineering that can be used in the present invention are described in Molecular Cloning: A Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), Gene Expression Technology (Methods in Enzymology, Vol. 185, D. Goeddel, ed., 1991. Academic Press, San Diego, CA), "Guide to Protein Purification" in Methods in Enzymology (MP Deutshcer, ed., (1990) Academic Press, Inc.); PCR Protocols: A Guide to Methods and Applications (Innis et al. 1990. Academic Press, San Diego, CA), Culture of Animal Cells: A Manual of Basic Technique, 2nd Edition (RI Freshney. 1987. Liss, Inc. New York, NY), and Gene Transfer and Expression Protocols, pp. 109-128, EJ Murray, ed., The Humana Press Inc., Clifton, NJ). Reagents, cloning vectors, and kits for genetic manipulations are available from commercial vendors such as BioRad, Stratagene, Invitrogen, ClonTech, and Sigma-Aldrich Co.

[0134] Human antibodies can also be produced in transgenic animals (e.g., mice) that are capable of producing a complete repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, homozygous deletion of the antibody heavy chain joining region (JH) gene in chimeric and germline mutant mice has been described, resulting in complete inhibition of endogenous antibody production. Transferring human germline immunoglobulin gene arrays into such germline mutant mice results in the production of human antibodies after antibody challenge. See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggemann et al., Year in Immuno., 7:33 (1993); U.S. Pat. Nos. 5,545,806, 5,569,825, 5,591,669 (all to GenPharm); U.S. Pat. No. 5,545,807; and WO 97 / 17852. Such animals can be genetically engineered to produce human antibodies comprising the polypeptides of the described invention.

[0135] A variety of techniques have been developed for producing antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24: 107-117 (1992); and Brennan et al., Science, 229: 81 (1985)). However, these fragments can now be produced directly by recombinant host cells. Fab, Fv, and ScFv antibody fragments can all be expressed in and secreted from E. coli, thus allowing for the easy production of large amounts of these fragments. Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab')2 fragments (see, e.g., Carter et al., Bio / Technology 10: 163-167 (1992)). According to another approach, F(ab')2 fragments can be directly isolated from recombinant host cell cultures. Fab and F(ab')2 fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life are described in US Pat. No. 5,869,046. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner.

[0136] Single-chain antibodies can be selected using other techniques known in the art for selecting antibody fragments from libraries using enrichment techniques as an alternative to the techniques discussed previously, including but not limited to phage display, ribosome display (Hanes and Pluckthun, 1997, Proc. Nat. Acad. Sci. 94: 4937-4942), bacterial display (Georgiou et al., 1997, Nature Biotechnology 15: 29-34) and / or yeast display (Kieke, et al., 1997, Protein Engineering 10: 1303-1310). Single-chain antibodies can be selected from single-chain antibody libraries generated directly using filamentous phage technology. Phage display technology is known in the art (see, e.g., technology from Cambridge Antibody Technology (CAT)), as disclosed in U.S. Pat. Nos. 5,565,332; 5,733,743; 5,871,907; 5,872,215; 5,885,793; 5,962,255; 6,140,471; 6,225,447; 6,291650; 6,492,160; 6,521,404; 6,544,731; 6,555,313; 6,582,915; 6,593,081, and other U.S. family members relying on priority filing GB9206318 filed May 24, 1992, or applications; see also Vaughn, et al. 1996, Nature Biotechnology 14:309-314). Single-chain antibodies can also be designed and constructed using available recombinant DNA techniques, such as DNA amplification methods (eg, PCR), or possibly by using the corresponding hybridoma cDNA as a template.

[0137] Variant antibodies are also included in the scope of the present invention. Thus, variants of the sequences described in the present application are also included in the scope of the present invention. Other variants of antibody sequences with improved affinity can be obtained using methods known in the art, and are included in the scope of the present invention. For example, amino acid substitutions can be used to obtain antibodies with further improved affinity. Alternatively, codon optimization of nucleotide sequences can be used to improve translation efficiency in expression systems to generate antibodies.

[0138] Such variant antibody sequences will share 70% or more (i.e. 80%, 85%, 90%, 95%, 97%, 98%, 99% or greater) sequence identity with the sequences described in the present application. Such sequence identity is calculated relative to the full length of the reference sequence (i.e., the sequence described in the present application). As mentioned herein, the percentage identity is as determined using BLAST version 2.1.3 using the default parameters [Blosum 62 matrix; gap opening penalty = 11 and gap extension penalty = 1] specified by NCBI (National Center for Biotechnology Information; www.ncbi.nlm.nih.gov / ). For example, the present invention provides peptide sequences comprising at least about 5, 10, 15, 20, 30, 40, 50, 75, 100, 150 or more continuous peptides of one or more sequences disclosed herein and all intermediate lengths therebetween. As used herein, the term "intermediate length" is intended to describe any length between the recited values, such as 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, etc.; 21, 22, 23, etc.; 30, 31, 32, etc.; 50, 51, 52, 53, etc.; 100, 101, 102, 103, etc.; 150, 151, 152, 153, etc.

[0139] The present invention provides antibodies alone or in combination with other antibodies having broad neutralizing activity in serum, such as but not limited to VRCOl, anti-V3 loop, CD4bs, and CD4i antibodies and PG9 / PG16-like antibodies.

[0140] According to another embodiment, the present invention provides methods for preparing and administering HIV antibody compositions suitable for administration to humans or non-human primates having HIV infection, or at risk of HIV infection, in amounts and according to a schedule sufficient to induce a protective immune response against HIV, or a reduction in HIV virus, in humans.

[0141] According to another embodiment, the invention provides a vaccine comprising at least one antibody of the invention and a pharmaceutically acceptable carrier. According to one embodiment, the vaccine is a vaccine comprising at least one antibody described herein and a pharmaceutically acceptable carrier. The vaccine may comprise any combination of a plurality of antibodies having the characteristics described herein, and may further comprise neutralizing antibodies for HIV, which are known in the art.

[0142] It should be understood that the composition can be a single antibody or a combination of antibodies disclosed herein (which can be the same or different) to prevent or therapeutically treat the progression of various subtypes of HIV infection after vaccination. Such combinations can be selected based on the desired immunity. When the antibody is administered to an animal or a human, it can be combined with one or more pharmaceutically acceptable carriers, excipients, or adjuvants known to those of ordinary skill in the art. The composition may further comprise broadly neutralizing antibodies known in the art, including but not limited to VRC01, b12, anti-V3 loop, CD4bs, and CD4i antibodies and PG9 / PG16-like antibodies.

[0143] In addition, with respect to determining effective levels in patients to treat HIV, in particular, suitable animal models are available and have been widely implemented to evaluate the in vivo efficacy of various gene therapy regimens against HIV (Sarver et al. (1993b), see above). These models include mice, monkeys and cats. Even if these animals are not naturally susceptible to HIV disease, chimeric mouse models (e.g., SCID, bg / nu / xid, NOD / SCID, SCID-hu, immune-competent SCID-hu, BALB / c ablated by the bone marrow) reconstructed with human peripheral blood mononuclear cells (PBMC), lymph nodes, fetal liver / thymus or other tissues can be used with lentiviral vectors or HIV infection and used as models of HIV pathogenesis. Similarly, simian immunodeficiency virus (SIV) / monkey models can be used, and feline immunodeficiency virus (FIV) / cat models can also be used. When used for therapeutic treatment of AIDS, the pharmaceutical composition can contain other drugs combined with the carrier according to the present invention. These other drugs can be used in their traditional manner (e.g., as a medicament for treating HIV infection).

[0144] According to another embodiment, the present invention provides an antibody-based pharmaceutical composition comprising an effective amount of an isolated HIV antibody, or an affinity-matured form, which provides a preventive or therapeutic treatment option to reduce HIV virus infection. The antibody-based pharmaceutical composition of the present invention can be formulated by a variety of strategies known in the art (e.g., see McGoff and Scher, 2000, Solution Formulation of Proteins / Peptides: In McNally, EJ, ed. Protein Formulation and Delivery. New York, NY: Marcel Dekker; pp. 139-158; Akers and Defilippis, 2000, Peptides and Proteins as Parenteral Solutions. In: Pharmaceutical Formulation Development of Peptides and Proteins. Philadelphia, PA: Talyor and Francis; pp. 145-177; Akers, et al., 2002, Pharm. Biotechnol. 14: 47-127). A pharmaceutically acceptable composition suitable for administration to a patient will contain an effective amount of antibodies in a formulation that not only retains biological activity but also promotes maximum stability during storage within an acceptable temperature range. Depending on the desired formulation, the pharmaceutical composition may also include a pharmaceutically acceptable diluent, a pharmaceutically acceptable carrier and / or a pharmaceutically acceptable excipient, or any such vehicle commonly used to prepare a pharmaceutical composition for animal or human administration. The diluent is selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, physiological phosphate buffered saline, Ringer's solution, dextrose solution, and Hank's solution. The amount of excipients that can be used for the pharmaceutical composition or formulation of the present invention is to uniformly distribute the antibody between the compositions so that it can be uniformly dispersed when it is delivered to a subject in need thereof. It can be used to dilute the antibody to a certain concentration that provides the desired beneficial mitigation or healing results while minimizing any adverse side effects that may occur due to excessively high concentrations. It may also have a preservation effect. Thus, for antibodies with high physiological activity, more excipients are used. On the other hand, for any active ingredient that exhibits less physiological activity, smaller amounts of excipients will be employed.

[0145] The antibodies and antibody compositions described above or vaccine compositions comprising at least one antibody or combination of antibodies described herein can be administered for the prophylactic and therapeutic treatment of HIV viral infection.

[0146] The present invention also relates to an isolated polypeptide comprising novel light chain and heavy chain amino acid sequences, and the consensus sequences of the heavy chain and light chain of SEQ ID NO: 1 and 2, such as Figure 3 Listed in .

[0147] In other related embodiments, the present invention provides polypeptide variants encoding Figure 3 The amino acid sequences of the HIV antibodies listed in ; the consensus sequences of the heavy and light chains of SEQ ID NOs: 1 and 2. These polypeptide variants have at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%, or greater sequence identity compared to the polypeptide sequences of the present invention, as determined using the methods described herein (e.g., BLAST analysis using standard parameters). Those skilled in the art will recognize that these values ​​can be appropriately adjusted to determine the corresponding identity of the encoded proteins by taking into account amino acid similarity, etc.

[0148] The term "polypeptide" is used in its conventional sense, i.e., as a sequence of amino acids. Polypeptides are not limited to products of a specific length. Peptides, oligopeptides, and proteins are included in the definition of polypeptides, and such terms are used interchangeably herein unless otherwise expressly indicated. This term also includes post-expression modifications of polypeptides, such as glycosylation, acetylation, phosphorylation, etc., and other modifications known in the art (both naturally occurring and non-naturally occurring). A polypeptide can be a whole protein, or a subsequence thereof. A particular polypeptide of interest in the context of the present invention is an amino acid subsequence comprising CDR, VH, and VL that is capable of binding to an antigen or HIV infected cell.

[0149] Polypeptide "variants" when the term is used herein refer to polypeptides that generally differ from the polypeptides explicitly disclosed herein by one or more substitutions, deletions, additions and / or insertions. Such variants may be naturally occurring or may be generated synthetically, for example, by modifying one or more of the above-described polypeptide sequences of the invention as described herein and / or using any of a variety of techniques known in the art, and evaluating one or more biological activities of the polypeptide.

[0150] For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of its ability to bind to other polypeptides (e.g., antigens) or cells. Since it is the binding ability and properties of a protein that define its biological functional activity, substitutions of certain amino acid sequences, and therefore its underlying DNA coding sequence, may be made in a protein sequence, thereby obtaining a protein with similar properties. Thus, it is contemplated that various changes may be made in the peptide sequences of the disclosed compositions, or the corresponding DNA sequences encoding the peptides, without appreciable loss of their biological utility or activity.

[0151] In many cases, a polypeptide variant will contain one or more conservative substitutions. "Conservative substitutions" refer to substitutions in which an amino acid is substituted for another amino acid with similar properties, such that a person skilled in the art of peptide chemistry would expect that the secondary structure and hydropathic properties of the polypeptide will remain essentially unchanged.

[0152] Amino acid substitutions are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, etc. Exemplary substitutions that may be considered for various of the foregoing characteristics are well known to those skilled in the art and include: arginine and lysine; glutamic acid and aspartic acid; serine and threonine; glutamine and asparagine; and valine, leucine, and isoleucine.

[0153] "Homology" or "sequence identity" refers to the percentage of residues in a polynucleotide or polypeptide sequence variant that are identical to the non-variant sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology. In specific embodiments, polynucleotide and polypeptide variants have at least about 70%, at least about 75%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, or at least about 99% polynucleotide or polypeptide homology with a polynucleotide or polypeptide described herein.

[0154] Such variant polypeptide sequences will share 70% or more (i.e. 80%, 85%, 90%, 95%, 97%, 98%, 99% or more) sequence identity with the sequences described in the present application. In other embodiments, the invention described provides polypeptide fragments of various lengths of continuous segments comprising the amino acid sequences disclosed herein. For example, the invention provides peptide sequences comprising at least about 5, 10, 15, 20, 30, 40, 50, 75, 100, 150 or more continuous peptides of one or more sequences disclosed herein and all intermediate lengths therebetween.

[0155] The present invention also includes nucleic acid sequences encoding part or all of the light and heavy chains of the described inventive antibodies and fragments thereof.Due to the redundancy of the genetic code, variants of these sequences encoding the same amino acid sequence may exist.

[0156] The present invention also includes isolated nucleic acid sequences encoding Figure 3 The polypeptides of the heavy and light chains of the HIV antibodies listed in and the consensus sequences of the heavy and light chains of SEQ ID NOs: 1 and 2.

[0157] In other related embodiments, the described invention provides polynucleotide variants encoding Figure 3The peptide sequences of the heavy and light chains of the HIV antibodies listed in; the consensus sequences of the heavy and light chains of SEQ ID NOs: 1 and 2. These polynucleotide variants have at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, or greater sequence identity compared to the polynucleotide sequences of the present invention, as determined using the methods described herein (e.g., BLAST analysis using standard parameters). Those skilled in the art will recognize that these values ​​can be appropriately adjusted to determine the corresponding identity of the proteins encoded by the two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame arrangement, etc.

[0158] The terms "nucleic acid" and "polynucleotide" are used interchangeably herein to refer to single-stranded or double-stranded RNA, DNA, or mixed polymers. A polynucleotide may comprise genomic sequences, extragenomic sequences, and plasmid sequences, and smaller engineered gene segments that express polypeptides or can be adapted to express polypeptides.

[0159] "Isolated nucleic acid" refers to a nucleic acid that is substantially separated from other genomic DNA sequences and proteins or complexes such as ribosomes and polymerases that naturally accompany the native sequence. The term encompasses nucleic acid sequences that have been removed from their naturally occurring environment, and includes recombinant or cloned DNA isolates and chemically synthesized analogs or analogs biologically synthesized by heterologous systems. Substantially pure nucleic acids include isolated forms of nucleic acids. Thus, this refers to the nucleic acid as originally isolated, and does not exclude genes or sequences that were later manually added to the isolated nucleic acid.

[0160] Polynucleotide "variants" as the term is used herein refer to polynucleotides that generally differ from the polynucleotides explicitly disclosed herein by one or more substitutions, deletions, additions and / or insertions. Such variants may be naturally occurring or may be generated synthetically, for example, by modifying one or more polynucleotide sequences of the invention as described herein and / or using any of a variety of techniques known in the art, and evaluating one or more biological activities of the encoded polypeptide.

[0161] Modifications can be made in the structure of the polynucleotides describing the invention and still obtain functional molecules encoding variants or derivative polypeptides having desired characteristics. When it is desired to change the amino acid sequence of a polypeptide to create an equivalent of the polypeptide of the present invention, or even an improved variant or part, one skilled in the art will change one or more codons of the encoding DNA sequence.

[0162] Typically, polynucleotide variants contain one or more substitutions, additions, deletions and / or insertions such that the immunogenic binding properties of the polypeptide encoded by the variant polynucleotide are not substantially diminished relative to the polypeptide encoded by the polynucleotide sequence specifically set forth herein.

[0163] In other embodiments, the invention described provides polynucleotide fragments comprising various lengths of continuous segments of sequences identical or complementary to one or more sequences disclosed herein. For example, the invention provides polynucleotides comprising at least about 10, 15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500 or 1000 or more continuous nucleotides of one or more sequences disclosed herein and all intermediate lengths therebetween, and encompassing any length between the cited values, such as 16, 17, 18, 19, etc.; 21, 22, 23, etc.; 30, 31, 32, etc.; 50, 51, 52, 53, etc.; 100, 101, 102, 103, etc.; 150, 151, 152, 153, etc.; and including all integers from 200-500; 500-1,000.

[0164] In another embodiment of the present invention, a polynucleotide composition is provided that is capable of hybridizing to a polynucleotide sequence provided herein or a fragment thereof or its complementary sequence under medium to high stringency conditions. Hybridization techniques are well known in the field of molecular biology. For illustration, moderate stringency conditions suitable for testing the hybridization of the polynucleotides of the present invention with other polynucleotides include pre-washing in a solution of 5x SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); washing overnight in 5x SSC at 50-60°C; followed by washing twice at 65°C for 20 minutes, each time with 2x, 0.5x, and 0.2x SSC containing 0.1% SDS. Those skilled in the art will appreciate that hybridization stringency can be easily manipulated, such as by changing the salt content of the hybridization solution and / or the temperature at which hybridization is performed. For example, in another embodiment, suitable highly stringent hybridization conditions include those described above, except that the hybridization temperature is increased, for example, to 60-65°C or 65-70°C.

[0165] In some embodiments, the polypeptide encoded by the polynucleotide variant or fragment has the same binding specificity as the polypeptide encoded by the native polynucleotide (i.e., specifically or preferentially binds to the same epitope or HIV strain). In some embodiments, the described polynucleotides, polynucleotide variants, fragments, and hybridizing sequences encode a polypeptide having at least about 50%, at least about 70%, and at least about 90% of the binding activity level of the polypeptide sequences explicitly listed herein.

[0166] The polynucleotides describing the invention or fragments thereof (regardless of the coding sequence itself) can be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, etc., so that their overall length can vary considerably. Nucleic acid fragments of almost any length are employed. For example, many embodiments of the present invention include exemplary polynucleotide segments having an overall length of about 10,000, about 5,000, about 3,000, about 2,000, about 1,000, about 500, about 200, about 100, about 50 base pairs, etc. (including all intermediate lengths).

[0167] The present invention further includes within its scope vectors such as expression vectors comprising the nucleic acid sequences according to the present invention. Cells transformed with such vectors are also included within its scope.

[0168] The present invention also provides vectors and host cells comprising nucleic acids of the present invention, and recombinant techniques for generating polypeptides of the present invention. Vectors of the present invention include those that can replicate in any type of cell or organism, including, for example, plasmids, bacteriophages, cosmids, and minichromosomes. In some embodiments, the vectors comprising the polynucleotides describing the invention are vectors suitable for propagation or replication of the polynucleotides, or vectors suitable for expressing the polypeptides describing the invention. Such vectors are known in the art and are commercially available.

[0169] "Vector" includes shuttle and expression vectors. Typically, plasmid constructs will also include a replication origin (e.g., ColE1 replication origin) and a selection marker (e.g., ampicillin or tetracycline resistance), which are used for replication and selection of plasmids in bacteria, respectively. "Expression vector" refers to a vector containing the necessary control sequences or regulatory elements for expressing antibodies (including antibody fragments of the present invention) in bacteria or eukaryotic cells.

[0170] As used herein, the term "cell" can be any cell, including but not limited to cells of eukaryotic multicellular species (e.g., in contrast to unicellular yeast cells), such as, but not limited to, mammalian cells or human cells. A cell can exist as a single entity, or can be part of a larger collection of cells. Such a "larger collection of cells" can include, for example, cell cultures (mixed or pure), tissues (e.g., endothelium, epidermis, mucosa, or other tissues), organs (e.g., lungs, liver, muscles, and other organs), organ systems (e.g., circulatory system, respiratory system, gastrointestinal system, urinary system, nervous system, integumentary system, or other organ systems), or organisms (e.g., birds, mammals, etc.).

[0171] The polynucleotides of the present invention can be synthesized in whole or in part, then combined and inserted into a vector using conventional molecular and cell biological techniques (including, for example, using suitable restriction sites and restriction enzymes to subclone the polynucleotides into a linearized vector). The polynucleotides describing the invention are amplified by polymerase chain reaction using oligonucleotide primers complementary to each strand of the polynucleotide. These primers also include restriction enzyme cleavage sites to facilitate subcloning into a vector. Replicable vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, and one or more markers or selection genes.

[0172] In order to express the polypeptide of the present invention, the nucleotide sequence encoding the polypeptide or a functional equivalent can be inserted into a suitable expression vector (i.e., a vector containing the elements necessary for the transcription and translation of the inserted coding sequence). Methods known to those skilled in the art can be used to construct expression vectors containing sequences encoding the polypeptide of interest and suitable transcription and translation control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described in, for example, Sambrook, J., et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview, NY and Ausubel, FM, et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York.NY.

[0173] The present invention also provides a kit that can be used to implement diagnostic and prognostic assays using antibodies, polypeptides and nucleic acids of the present invention. The kit of the present invention comprises a suitable container, which comprises HIV antibodies, polypeptides or nucleic acids of the present invention in a labeled or unlabeled form. In addition, when antibodies, polypeptides or nucleic acids are supplied in a labeled form suitable for indirect binding assays, the kit further comprises reagents for implementing suitable indirect assays. For example, the kit can include one or more suitable containers, which contain enzyme substrates or derivatizing agents according to the properties of the marker. Control samples and / or instructions can also be included. The present invention also provides a kit for detecting the presence of HIV antibodies of the present invention or nucleotide sequences of HIV antibodies in biological samples by PCR or mass spectrometry.

[0174] As used herein, "label" refers to a detectable compound or composition that is conjugated directly or indirectly to an antibody to generate a "labeled" antibody. Labels may also be conjugated to polypeptides and / or nucleic acid sequences disclosed herein. Labels may be detectable by themselves (e.g., radioisotope labels or fluorescent labels) or, in the case of enzymatic labels, may catalyze a chemical change in a detectable substrate compound or composition. The antibodies and polypeptides of the described invention may also be modified to include an epitope tag or label, for example, for purification or diagnostic applications. Suitable detection means include the use of labels such as, but not limited to, radionucleotides, enzymes, coenzymes, fluorescent agents, chemiluminescent agents, chromogens, enzyme substrates or cofactors, enzyme inhibitors, prosthetic group complexes, free radicals, particles, dyes, etc.

[0175] According to another embodiment, the invention provides a diagnostic method. The diagnostic method generally involves contacting a biological sample obtained from a patient (such as, for example, blood, serum, saliva, urine, sputum, cell swab sample, or tissue biopsy) with HIV antibodies and determining whether the antibody preferentially binds to the sample compared to a control sample or a predetermined cutoff value, thereby indicating the presence of HIV virus.

[0176] According to another embodiment, the present invention provides a method for detecting the presence of HIV antibodies of the present invention in a biological sample from a patient. The detection method generally involves obtaining a biological sample from a patient, such as, for example, blood, serum, saliva, urine, sputum, a cell swab sample, or a tissue biopsy, and isolating HIV antibodies or fragments thereof, or nucleic acids encoding HIV antibodies, and determining the presence of HIV antibodies in the biological sample. In addition, the present invention provides a method for detecting the nucleotide sequence of HIV antibodies in a cell. The nucleotide sequence of HIV antibodies can also be detected using primers disclosed herein. The presence of HIV antibodies in a biological sample from a patient can be determined using known recombinant techniques and / or the use of a mass spectrometer.

[0177] In another embodiment, the invention provides a method for detecting HIV antibodies in a biological sample, the HIV antibodies comprising a heavy chain comprising a highly conservative consensus sequence and a light chain comprising a highly conservative consensus sequence, the method comprising obtaining a biological sample containing immunoglobulins from a mammalian subject, separating HIV antibodies from the sample, and identifying the highly conservative consensus sequences of the heavy and light chains. The biological sample can be blood, serum, saliva, urine, sputum, cell swab samples, or tissue biopsies. The amino acid sequence can be determined by methods known in the art (including, for example, PCR and mass spectrometry).

[0178] The term "assessment" includes any form of measurement, and includes determining whether an element is present or not. The terms "determine", "measure", "estimate", "assess" and "test" are used interchangeably, and include quantitative and qualitative determinations. Assessments can be relative or determinative. "Assessing the presence" includes determining the amount of something present, and / or determining whether it is present or absent. As used herein, the terms "determine", "measure", and "assess" and "test" are used interchangeably, and include both quantitative and qualitative determinations.

[0179] II. Methods of Reducing Viral Replication

[0180] Further provided are methods for reducing HIV viral titer, viral replication, viral proliferation, or increased amounts of HIV viral proteins. According to another aspect, the method comprises administering to a subject an amount of HIV antibodies sufficient to reduce HIV titer, viral replication, or increased amounts of HIV proteins of one or more HIV strains or isolates in the subject.

[0181] According to another embodiment, the invention provides a method of reducing viral replication or spread of HIV infection to other host cells or tissues comprising contacting a mammalian cell with an antibody or portion thereof that binds to an antigenic epitope on gp120.

[0182] III. Treatment Methods

[0183] According to another embodiment, the present invention provides a method for treating a mammal infected with a viral infection (such as, for example, HIV), comprising administering to the mammal a pharmaceutical composition comprising an HIV antibody disclosed herein. According to one embodiment, the method for treating a mammal infected with HIV comprises administering to the mammal a pharmaceutical composition comprising an antibody of the present invention or a fragment thereof. The composition of the present invention may comprise more than one antibody having the disclosed characteristics (e.g., multiple antibodies or antibody pools). It may also include other HIV neutralizing antibodies as known in the art, such as, but not limited to, VRC01, PG9, and b12.

[0184] Passive immunization has been demonstrated to be an effective and safe strategy for the prevention and treatment of viral diseases. (See, e.g., Keller et al., Clin. Microbiol. Rev. 13:602-14 (2000); Casadevall, Nat. Biotechnol. 20:114 (2002); Shibata et al., Nat. Med. 5:204-10 (1999); and Igarashi et al., Nat. Med. 5:211-16 (1999). Passive immunization using human monoclonal antibodies provides an immediate treatment strategy for the emergency prevention and treatment of HIV.

[0185] Subjects at risk for HIV-related diseases or conditions include patients who have come into contact with infected individuals or have been exposed to HIV in some other way. Administration of a prophylactic agent can occur before the manifestation of symptoms characteristic of an HIV-related disease or condition, such that the disease or condition is prevented or, alternatively, delayed in its progression.

[0186] For in vivo treatment of human and non-human patients, a pharmaceutical formulation comprising HIV antibodies of the present invention is administered or provided to the patient. When used for in vivo treatment, the antibody of the present invention is administered to the patient in a therapeutically effective amount (i.e., the amount of the viral load of the patient is eliminated or reduced). According to known methods (such as intravenous administration, for example, by bolus or by continuous infusion over a period of time, the antibody is administered to human patients by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intraarticular, intrasynovial, intrathecal, oral, surface, or inhalation routes. The antibody can be administered parenterally, (when possible) at the target cell site, or intravenously. In some embodiments, the antibody is administered by intravenous or subcutaneous administration. The therapeutic composition of the present invention can be administered to a patient or subject systemically, parenterally or locally. The above-mentioned parameters for evaluating the successful treatment and improvement of the disease are easily measurable by conventional procedures familiar to physicians.

[0187] For parenteral administration, the antibody can be formulated into a unit dose injectable form (solution, suspension, emulsion) in conjunction with a pharmaceutically acceptable parenteral vehicle. Examples of such vehicles include, but are not limited to, water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Non-aqueous vehicles include, but are not limited to, fixed oils and ethyl oleate. Liposomes can be used as carriers. The vehicle can contain a small amount of additives such as substances that enhance tension and chemical stability, such as, for example, buffers and preservatives. The antibody can be formulated in such vehicles at a concentration of about 1 mg / ml to 10 mg / ml.

[0188] Dosage and dosage regimen depend on multiple factors that physicians are easily determined, such as the nature of infection, such as its therapeutic index, patient and patient history.In general, the antibody of therapeutic effective amount is applied to the patient.In some embodiments, the antibody amount applied is in the range of about 0.1mg / kg to about 50mg / kg patient weight.According to the type and severity of infection, the antibody of about 0.1mg / kg to about 50mg / kg body weight (for example, about 0.1-15mg / kg / dosage) is the initial candidate dose applied to the patient (regardless of for example, by one or more different applications or by continuous infusion).The progress of this therapy is easily monitored by conventional methods and determination methods and based on the standards known to other technicians in the field of physicians or physicians.The above-mentioned parameters that are easily measurable for assessing successful treatment and disease improvement by the conventional procedures familiar to physicians.

[0189] Other treatment regimens can be combined with the administration of HIV antibodies of the present invention. Combination administration includes co-administration using different formulations or single drug formulations, and continuous administration in any order, wherein preferably, there is a time period during which two (or all) active agents are simultaneously applied to their physiological activity. Such conjoint therapy can result in a synergistic therapeutic effect. The above-mentioned parameters for evaluating successful treatment and disease improvement are easily measurable by conventional procedures familiar to physicians.

[0190] The terms "treat" or "treating" or "alleviate" are used interchangeably and refer to both therapeutic treatment and preventative or prophylactic measures; wherein the object is to prevent or slow down (reduce) the targeted pathological condition or disorder. Subjects in need of treatment include those already having the disorder as well as those susceptible to having the disorder or those for whom the disorder is to be prevented. A subject or mammal is successfully "treated" for an infection if, after receiving a therapeutic amount of an antibody according to the methods of the invention, the patient shows an observable and / or measurable reduction or absence of one or more of the following: a decrease in the number of infected cells or an absence of infected cells; a decrease in the percentage of total cells infected; and / or a reduction to some extent in one or more symptoms associated with a specific infection; reduced morbidity and mortality, and improvement in quality of life issues. The above parameters for assessing successful treatment and disease improvement are readily measurable by routine procedures familiar to physicians.

[0191] The term "therapeutically effective amount" refers to an amount of an antibody or drug effective to treat a disease or disorder in a subject or mammal.

[0192] Administration "in combination with" one or more additional therapeutic agents includes simultaneous (concurrent) and sequential administration in any order.

[0193] As used herein, "carrier" includes a pharmaceutically acceptable carrier, excipient or stabilizer that is nontoxic to cells or mammals exposed thereto at the doses and concentrations employed. Often, a physiologically acceptable carrier is an aqueous pH buffered solution. Examples of physiologically acceptable carriers include, but are not limited to, buffers such as phosphates, citrates, and other organic acids; antioxidants, including but not limited to ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as but not limited to serum albumin, gelatin, or immunoglobulins; hydrophilic polymers, such as but not limited to polyvinylpyrrolidone; amino acids such as but not limited to glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates, including but not limited to glucose, mannose, or dextrins; chelating agents, such as but not limited to EDTA; sugar alcohols, such as but not limited to mannitol or sorbitol; salts forming counterions, such as but not limited to sodium; and / or nonionic surfactants, such as but not limited to TWEEN.; polyethylene glycol (PEG), and PLURONICS.

[0194] In the case of providing range values, it is understood that each intermediate value between the upper and lower limits of the range (to one tenth of the lower limit unit, unless the context clearly indicates otherwise) and any other specified or intermediate values ​​in the specified range are included in the present invention. The upper and lower limits of these smaller ranges that can be independently included in the smaller ranges are also included in the present invention, subject to any explicitly excluded limits in the specified range. In the case where the specified range includes one or two limits, the present invention also includes the range that excludes any two of those included limits.

[0195] Example 1

[0196] This example describes the materials and methods used in Examples 2-5 described below.

[0197] Following gp140-specific single B cell capture cloning and generation of HIV antibodies, as previously described (Mouquet, H. et al. PLoS One 6, e24078 (2011); Tiller, T. et al. J Immunol Methods 329, 112-24 (2008); and Scheid, JF et al. Nature 458, 636-40 (2009)). PGT121 was generated by substituting residues 10-1074 at HC positions 32, 53, 54, 58, 97, 1001 into PGT121. GM and 10-1074 GM The binding properties of anti-gp140 antibodies to HIV Env protein were determined by ELISA, SPR and glycan microarray assays as previously described (Scheid, JF et al. Science 333, 1633-7 (2011); Walker, LM et al. Nature 477, 466-70 (2011); and Mouquet, H. et al. PLoS One 6, e24078 (2011)). Neutralization was assessed using (i) a luciferase-based assay in TZM.b1 cells and (ii) a PBMC-based assay using infection with major HIV-1 variants as previously described (Li, M. et al. J Virol 79, 10108-25 (2005); Euler, Z. et al. Journal of virology 85, 7236-45 (2011); and Bunnik, EM et al. Nature medicine 16, 995-7 (2010)). The structures of PGT121 ("without ligand" and "with ligand"), 10-1074 and GL Fab fragments were solved by molecular replacement to and Resolution.

[0198] Single B cell RT-PCR and Ig gene analysis

[0199] Single cell sorting of gp140 from PBMC of patient 10 (pt10; referred to as patient 17 in Nature 477(7365):466-470) + CD19 + IgG + B cells, cDNA synthesis, and nested PCR amplification of Ig genes were performed in a previous study (PLoS One 6(9): e24078). The Igλ gene expressed by the PGT121 clonal variant was PCR amplified using a forward primer further upstream in the leader sequence (L-Vλ3-21*02: 5'CTGGACCGTTCTCCTCCTCG 3') to avoid regions of potential mutations ( 31 All PCR products were sequenced and analyzed for Ig gene usage, CDR3 analysis, and the number of VH / Vκ somatic hypermutations (IgBLAST; http: / / www.ncbi.nlm.nih.gov / igblast and http: / / www.imgt.org). Multiple sequence alignments were performed using the MacVector program (v.12.5.0) with the ClustalW analysis function (default parameters) and used to generate dendrograms by the Neighbor Joining method (with Best tree mode and outgroup rooting). Alternatively, dendrograms were generated using the UPGMA method (with Best tree mode).

[0200] The IgG4-positive cells were stained with IgBLAST (http: / / www.ncbi.nlm.nih.gov / igblast) and The germline (GL) precursor gene segments of PGT121-like and 10-1074-like antibodies were identified as V H 4-59*01, J H 6*03, V L 3-21*02 and J L3*02. (These gene segments are the most commonly used in the human antibody repertoire (PLoS One 6(8): e22365; Immunogenetics 64(5): 337-350). To establish a representative GL ancestral sequence, we used IgBLAST (http: / / www.ncbi.nlm.nih.gov / igblast) to align the IgH and IgL sequences of 10-996 (the antibody with the fewest somatic hypermutations) with the GL sequence. The mature V H and J H The gene segment was replaced with its GL counterpart and the 10-996 sequence of the CDRH3 region involving the N region nucleotides and the D H Gene segments were used to construct GL IgH sequences. L 3-21*02 and J L 3*02 gene segment sequence assembled GL IgL sequence.

[0201] Antibody cloning and generation

[0202] The purified digested PCR products were cloned into human Igγ1- or Igλ expression vectors (J Immunol Methods 329(1-2): 112-124). The vectors containing the IgH and Igλ genes were then sequenced and compared with the initial PCR product sequence. PGT121 and 10-303 shared the same Igλ gene and had one amino acid difference in position 2 of the IgH gene ( Figure 4 ); therefore, to generate PGT121 IgG, we used the 10-303Igλ gene and the PGT121IgH gene, which was generated by introducing a single substitution (V2M) into the 10-303IgH gene by site-directed mutagenesis (QuikChange Site-Directed Mutagenesis Kit; Stratagene). To generate His-tagged Fab, PGT121 and 10-1074V H The gene was subcloned into our standard Igγ1 vector (Science 301(5638):1374-1377) by modifying it to encode an IgG1 C followed by a 6x-His tag. H 1 domain generated 6xHis-IgCγ1 expression vector. GM (S32Y, K53D, S54R, N58T, H97R, T1001Y) and 10-1074 GM The IgH DNA fragments of the (Y32S, D53K, R54S, T58N, R97H, Y1001T) mutant antibodies were obtained using a synthetic minigene (IDT) and subcloned into the Igγ1 expression vector.

[0203] Listed below are 10-1074 GM The heavy chain sequence of 10-1074 wherein the mutation is underlined. GM The light chain sequence of is identical to that of 10-1074.

[0204]

[0205]

[0206] Antibodies and Fab fragments were produced by transiently transfecting IgH and IgL expression plasmids into exponentially growing HEK 293T cells (ATCC, CRL-11268) using the polyethyleneimine (PEI) precipitation method (PLoS One 6(9): e24078). IgG antibodies were affinity purified using protein G Sepharose beads (GE Healthcare) according to the manufacturer's instructions. TM The Fab fragments were affinity purified using Cobalt Resin (Thermo scientific) as described below.

[0207] HIV-1 Env protein

[0208] Alanine mutations were introduced into the pYU-2gp120 vector (a gift from J. Sodroski, Harvard Medical School) at positions 301 to 303 (Asn-Asn-Thr), 324 to 325 (Gly-Asp), and 332 (Asn) (HXBc2 amino acid numbering) using the QuikChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions. gp120 and Asn406 gp120 Single alanine mutations were introduced into pYU-2gp120 at each PNGS between N332A The site-directed mutations were confirmed by DNA sequencing.

[0209] The genes encoding YU-2gp140 (Journal of Virology 74(12):5716-5725), YU-2gp120, and HXB2c gp120 were used. coreHEK 293T cells were transfected with expression vectors for YU-2 gp120 mutant proteins (Nature 393(6686):648-659), HXB2c 2CCcore (PLoS Pathog 5(5):e1000445), and YU-2 gp120 mutant proteins. kif ), 25 μM kifunine (Enzo Life Sciences) was added at the time of transfection. The culture supernatant was harvested and concentrated using a centrifugal-based filtration device (Vivacell 100, Sartorius Stedim BiotechGmbh) that allows the sample to be buffered to 10 mM imidazole, 50 mM sodium phosphate, 300 mM sodium chloride (pH 7.4). TM Proteins were purified by affinity chromatography using cobalt resin (Thermo scientific) according to the manufacturer's instructions.

[0210] For deglycosylation reactions, 50 μg of YU-2gp120 produced by HEK 293T cells in PBS was lysed with 200 U PNGase F (New England Biolabs) or 10,000 U Endo H in its corresponding reaction buffer without denaturant. f (New England Biolabs) at 37°C overnight. After buffer exchange with PBS using ELISA Ultra (Millipore), glycosidase-treated gp120s (200 ng) were examined by SDS-PAGE using 4-12% NuPAGE gel (Invitrogen) followed by silver staining (Pierce Silver Staining Kit, Thermo Scientific).

[0211] ELISA

[0212] High binding 96-well ELISA plates (Costar) were coated with 100 ng / well purified gp120 in PBS overnight. After washing, the plates were blocked for 2 hours with 2% BSA, 1 μM EDTA, 0.05% Tween-PBS (blocking buffer) and then incubated for 2 hours with IgG at a concentration of 26.7 nM (or 427.2 nM for ELISA using YU-2 gp120 dual glycan mutants) and seven serial 1:4 dilutions in PBS. After washing, 1 mouse was incubated with HRP-conjugated goat anti-human IgG antibody (Jackson ImmunoReseach) (0.8 μg / ml in blocking buffer) and the plates were visualized by adding HRP chromogenic substrate (ABTS solution, Invitrogen) (PLoS One 6(9): e24078). The antibodies were tested for the selected gp120 using the peptide-ELISA method described previously. V3 Binding of overlapping peptides.

[0213] For competition ELISA, gp120 coated plates were blocked with blocking buffer for 2 hours and then incubated with biotinylated antibodies (26.6 nM for PGT121, 0.21 nM for 10-1074, 0.43 nM for 10-996 and 1.67 nM for 10-1369) in 1:2 serial dilutions of antibody competitors in PBS (IgG concentration range of 5.2 to 667 nM) for 2 hours. Plates were visualized using HRP-conjugated streptavidin (Jackson ImmunoReseach) (0.8 μg / ml in blocking buffer) as described above. All experiments were performed at least in duplicate.

[0214] Glycan microarray analysis

[0215] Microarrays were generated by robotically printing lipid-linked glycan probes (neoglycolipids) onto nitrocellulose-coated glass slides (Methods Mol Biol 808: 117-136) in duplicate at two levels (2 and 5 fmol / spot). Binding assays were performed using microarrays containing 15 neoglycolipids derived from high-mannose and complex-type N-glycans. Figure 7 The sequence of the probe is shown in A. Briefly, antibodies were tested at 50 μg / ml and binding was detected with biotinylated anti-human IgG (Vector) followed by AlexaFluor 647-labeled streptavidin (Molecular Probes).

[0216] Surface Plasmon Resonance

[0217] Experiments were performed using Biacore T100 (Biacore, Inc.) (Nature 467(7315): 591-595). Briefly, YU-2 gp140 and gp120 proteins were coupled with primary amines at a coupling density of 300 RU on a CM5 chip (Biacore, Inc.). Anti-gp120 IgG and germline precursor (GL) were injected on the flow cell at 1 μM and 10 μM, respectively, at a flow rate of 35 μl / min with a 3-minute binding and 5-minute dissociation phase. The sensor surface was regenerated by injecting 10 mM glycine-HCl pH 2.5 at a flow rate of 50 μl / min for 30 seconds. Dissociation (k) was calculated from kinetic analysis after background subtraction using a 1:1 binding model (Biacore T100 evaluation software) without bulk reflective index (RI) correction. d (s -1 )) and combined with (k a (M -1 s -1 ) and the binding constant (K D (M) or K A (M -1 ). The binding constant for a bivalent IgG calculated using a 1:1 binding model is referred to in textbooks as the “apparent” affinity to emphasize the K D Values ​​include potential avidity effects.

[0218] Neutralization assay

[0219] Virus neutralization was assessed using a luciferase-based assay in TZM.bl cells (J Virol 79(16): 10108-10125). The HIV-1 pseudoviruses tested contained primarily tier-2 and tier-3 viruses (Journal of virology 84(3): 1439-1452) (Tables 4 and 5). In wild-type cells treated with 25 μM kifunine (Enzo Life Sciences) Figure 8 C) or in HEK 293S GnTI - / - cell( Figure 8 D) High mannose-only pseudovirus was generated. Nonlinear regression analysis was used to calculate the concentration at which half-maximal inhibition (IC 50Values). Neutralization activity was also assessed using a previously characterized PBMC-based assay using infection with major HIV-1 variants (n = 95) isolated from clade B infected donors with known seroconversion data between 1985 and 1989 ("historical seroconverters", n = 14) or between 2003 and 2006 ("contemporary seroconverters", n = 21) (Journal of virology 85 (14): 7236-7245; Nat Med 16 (9): 995-997). Neutralization activity of each antibody was calculated using GraphPad Prism software (v5.0b) as the area under the best fit curve fitted relative to the IC range of 0.001 to 50 μg / ml. 50 The relative area under the curve (RAUC) values ​​were obtained by normalizing all AUC values ​​to the highest value (obtained using 10-1074).

[0220] Statistical analysis

[0221] Statistical analysis was performed using GraphPad Prism software (v5.0b). Neutralization potency versus apparent binding affinity of antibodies against gp120 and gp140 in the TZM-b1 assay against a selected set of nine virus strains was analyzed using the Spearman correlation test. The Mann Whitney test was used to compare: (i) the affinity of antibodies belonging to the PGT121 or 10-1074 group for gp120 / gp140, and (ii) the neutralizing activity against viruses isolated from historical and contemporary seroconverters.

[0222] Crystallization and structure determination

[0223] PGT121, 10-1074 and 10-996GL Fabs were expressed with 6x-His tags for crystallization. 2+ -NTA affinity (Qiagen) and Superdex20010 / 300 (GE Healthcare) size exclusion chromatography were used to purify Fab from the supernatant of transiently transfected HEK 293-6E cells. For crystals of ligand-free PGT121 Fab, PGT121 IgG was isolated from the supernatant of transiently transfected HEK 293-6E cells by protein A affinity chromatography (Pierce), and Fab fragments were obtained by papain cleavage of IgG and further purification using Superdex20010 / 300 (GE Healthcare) size exclusion chromatography.

[0224] Purified Fab was concentrated to 8-20 mg / mL in PBS buffer ("unliganded" PGT121, 8 mg / mL; 10-1074 and GL, 20 mg / mL). "Liganded" PGT121 Fab crystals were prepared from protein samples (final concentration: 15 mg / mL) mixed with 3-fold molar excess of NA2 glycan and incubated at 20°C for 2 hours. Crystals were used in 400 nL droplets using a 1:1 protein to reservoir ratio. Crystallization conditions were screened at 20°C using a crystallization robot (TTP labs). Crystals of "ligand-free" PGT121 Fab (P212121; a=56.8, b=74.7, ), and the crystals of “liganded” PGT121 Fab (P212121; a=67.8, b=67.8, ) was grown in 17% PEG 10,000, 0.1M Bis-Tris pH 5.5, 0.1M CH3-COcHNH4. Crystals of 10-1074 Fab (P21; a=61.4, b=40.3, β=95.39°), and the crystals of GL Fab (P21; a=54.9, b=344.7, = 91.95°) were grown in 20% PEG 3,350, 0.24M sodium malonate pH 7.0, 10 mM MnCl. Crystals were cryoprotected by soaking in a mother liquor containing 20% ​​glycerol ("unliganded" and "liganded" PGT121 Fab) or 20% ethylene glycol (10-1074 Fab and GL Fab) followed by rapid freezing in liquid nitrogen.

[0225] The 6M pixel detector (Dectris) was used at the Stanford Synchrotron Radiation Lightsource (SSRL) at beamline 12-2 Diffraction data were collected. The data were indexed, merged and scaled using XDS. Using data obtained from "ligand-free" PGT121 Fab crystals, we used Phenix to search for the C of the model PGT128 Fab (PDB code 3PV3) using two methods after omitting residues in the CDRH3 and CDRL3 loops. H -C L domain and 2F5 (PDB code 3IDJ) VH -V L We then used the "unliganded" PGT121 structure as a search model to find molecular replacements for the "liganded" PGT121 Fab (one Fab per asymmetric unit), 10-1074 Fab (one Fab per asymmetric unit), and GL (four Fabs per asymmetric unit).

[0226] Iterative refinement (including non-crystallographic symmetry restraints of GL) was performed using Phenix and manually fitting the model to the electron density map using Coot. The atomic model was refined to Resolution (for PGT121 Fab) (R 工作 =21.6%; R 游离 =26.4%), Resolution (for 10-1074Fab) (R 工作 =18.7%; R 游离 =22.3%), Resolution (for 4 GL Fab molecules) (R 工作 =19.4%; R 游离 =23.7%), and Resolution (for “liganded” PGT121 Fab (R 工作 =20.1%; R 游离 =24.9%). The atomic model of PGT121 Fab contained 95.2%, 4.9% and 0.0% residues in the favored, allowed and disallowed regions of the Ramachandran plot, respectively (10-1074 Fab: 98.8%, 0.9%, 0.2%; GL Fab: 96.0%, 3.8%, 0.23%; "liganded" PGT121 Fab: 96.7%, 3.1%, 0.2%). Molecular visualization was performed using PyMOL and a map of the Fab structure was generated. The buried surface area of ​​the probe was calculated using Areaimol (CCP4 Suite).

[0227] The Fab structures were aligned using the Super script in PyMOL. Pairwise Cα alignment was performed using PDBeFold.

[0228] Example 2: Advantages and diversity of PGT121 clonotypes

[0229] YU-2gp140 trimer was used as "bait" to isolate gp140-specific IgG memory B cells from an African donor infected with clade A. 87 matching immunoglobulin heavy (IgH) and light (IgL) chain genes corresponding to 23 unique clonal families were identified. The IgH anti-gp140 repertoire was dominated by one clonal family accounting for approximately 28% of all expanded B cell clones. This B cell family corresponds to the same clone as PGT121-123 (Nature 477 (7365): 466-470) and contains 38 members, 29 of which are unique variants at the nucleotide level (Table 3). Based on its IgH nucleotide sequence, the PGT121 family is divided into two groups: a PGT121-like group containing PGT121-123 and 9 closely related variants, and a second group 10-1074-like containing 20 members. Although our conventional primers (J Immunol Methods 329(1-2):112-124; Science 301(5638):1374-1377) did not amplify the IgL genes expressed by the PGT121B cell clone due to nucleotide deletions in the region encoding framework region 1, 24 of the 38 Igλ genes were obtained using new Igλ-specific primers designed to amplify heavily somatically mutated genes (Table 3). Consistent with the high level of hypermutation in IgH genes (average of 18.2% of Vλ genes), the amplified Igλ genes were highly mutated (average of 18.2% of Vλ genes) and carried nucleotide deletions (12 to 21 nucleotides) in framework region 1 (FWR1) and a 9-nucleotide insertion (FWR3) in framework region 3 (FWR4). Figure 3 B and Table 3).

[0230] Figure 3 Sequence alignments of three PGT antibodies (PGT-121, -122, and -123), seven PGT121 and 10-1074 clone variants (10-259, 10-303, 10-410, 10-847, 10-996, 10-1074, 10-1121, 10-1130, 10-1146, 10-1341, 10-1369, and 10-1074GM), possible germline (GL), and consensus sequences are shown in (a) and 3(b). Sequences of the corresponding heavy chain variable regions, light chain variable regions, heavy chain CDRs, and light chain CDRs under both the IMGT and KABT systems are listed in Table 1 below. The assigned sequence identification numbers for the sequences under the KABT system are listed in Table 2 below:

[0231]

[0232]

[0233]

[0234] Table 2

[0235]

[0236] Eleven new unique variants were expressed (Table 3) and demonstrated binding to YU-2 gp120 and gp140 by ELISA and surface plasmon resonance (SPR). Unless otherwise noted, the gp120 and gp140 proteins used for these and other experiments were expressed in mammalian cells that can attach complex or high mannose N-glycans to PNGS. The level of reactivity with gp120 varied between antibodies belonging to the PGT121 and 10-1074 groups, with the latter exhibiting a higher apparent affinity ( Figure 3 A), which is mainly due to the slower dissociation of 10-1074 related antibodies from gp120 / gp140 ( Figure 4 B).

[0237] Example 3: PGT121 and 10-1074 epitopes

[0238] Asn332 near the V3 ring stem gp120 As reported to be essential for PGT121 binding and virus neutralization (Nature 477(7365):466-470), we therefore examined the role of V3 in antigen recognition by PGT121-like and 10-1074-like antibodies. 核心 ) or the HXB2 gp120 “core” protein that retained a portion of V3 (2CC-core), and the YU-2 gp120 mutant protein carrying a double alanine substitution in the V3 stem (gp120 GD324-5AA ) ELISA was performed. The antibodies tested showed reduced activity against variants lacking the V3 loop and gp120 when compared to intact YU-2 gp120. GD324-5AA of the reactivity, with the binding of group 10-1074 antibodies being the most affected ( Figure 5 A and B). These results suggest that recognition by both antibody groups involves a protein determinant cluster near the V3 loop. None of the antibodies bound overlapping peptides spanning V3, suggesting that the targeted epitope is discontinuous and / or requires a specific conformation that is not achieved by isolated peptides ( Figure 5 C).

[0239] Asn332 gp120 (Asn337 in the early numbering method gp120(J Proteome Res 7(4): 1660-1674)) is the N-terminal residue of the potential N-glycosylation site (PNGS) defined as the sequence Asn-X-Ser / Thr. gp120 To determine whether the novel PGT121- and 10-1074-group antibodies and / or their N-linked glycans are required for gp120 reactivity, we tested their activity against YU-2 gp120 by ELISA. N332A The N332A substitution reduced the binding of PGT121 and all new antibody variants, while its binding to mutant gp120 lacking adjacent glycosylation sites (gp120 NNT301-3AAA The reactivity of the mutant was unchanged. gp120 To investigate whether PNGS outside of PNGS affects the recognition of new antibodies, we constructed a series of 11 dual glycan mutants, among which the N332A mutation in YU-2gp120 is associated with the mutation at Asn262. gp120 and Asn406 gp120 All PGT121-like and 10-1074-like antibodies were expressed in combination with antibodies against gp120 N332A The affinities of β-catenin bound to each dual glycan mutant with comparable affinities.

[0240] To compare the overall glycan recognition of PGT121- and 10-1074-like antibodies, we examined their binding to YU-2 gp120 treated with PNGase F, which cleaves both complex and high-mannose N-glycans. Since gp120 cannot be completely enzymatically deglycosylated (unless it is denatured), PNGase F treatment results in partial deglycosylation of natively folded gp120 ( Figure 6 ). However, the difference in the reactivity of the two groups of antibodies was that partial deglycosylation of gp120 by PNGase F reduced the binding reactivity of all PGT121-like antibodies but none of the 10-1074-like antibodies ( Figure 6 C) Similar experiments with YU-2gp120 treated with Endo H (which cleaves high mannose, but not complex N-glycans) affected the binding of 10-1074-like antibodies over PGT121-like antibodies ( Figure 6 D).

[0241] N-glycan microarray revealed that 6 of 7 tested PGT121-like antibodies showed detectable binding to complex mono- or biantennary N-glycans terminated with galactose or α2-6-linked sialic acid, but no detectable binding to high-mannose glycans, confirming and extending previous reports of the lack of PGT121-123 binding to high-mannose N-glycans and the lack of competition of Man4 and Man9 dendrons for gp120 binding ( Figure 7 In comparison, the 10-1074-like antibody had no detectable binding to the protein-free glycan ( Figure 7 Although PGT121-like antibodies bind to protein-free complexes rather than high-mannose N-glycans, PGT121-like antibodies still bind to kifunine (gp120 kif YU-2gp120 ( Figure 8 B) Most PGT121-like antibodies exhibited small but reproducible binding to gp120 kif In contrast, the 10-1074-like antibody still fully bound to gp120 kif ( Figure 8 B) These results are consistent with the hypothesis that high mannose and complex N-glycans may contribute to the epitope of PGT121-like antibodies.

[0242] Epitope mapping experiments were performed by competition ELISA with two representative members of each group (PGT121 and 10-1369 for the PGT121-like group; 10-1074 and 10-996 for the 10-1074-like group). All four antibodies showed cross-competition, but PGT121 inhibited the binding of 10-996 and 10-1074 to gp120 more modestly than 10-996 and 10-1074 inhibited the binding of PGT121 to gp120. To further localize the targeted epitope, we used an anti-gp120 antibody that recognizes the crown of the V3 loop ( Figure 5 ), CD4bs, co-receptor binding sites (CD4-induced; CD4i), a population of high-mannose N-glycans (2G12) (Journal of virology 76(14):7293-7305; Proc Natl Acad Sci USA 102(38):13372-13377)), or the V3 loop and N-linked glycans at positions 301 and 332 (PGT128). Anti-V3 crown antibodies inhibited the binding of PGT121 and 10-1369, but did not interfere with the binding of 10-996 and 10-1074. PGT128 and (to a lesser extent) 2G12, but not CD4bs and CD4i antibodies, reduced the binding of all four antibodies to gp120.

[0243] Taken together, these data suggest that the V3 loop and Asn332 are involved in the recognition of PGT121 clone members. gp120 The sites of protein determinants near the relevant glycans. However, the clones fell into two families, the PGT121-like and the 10-1074-like groups, which differed in their affinity for gp120 and the role of the glycans in epitope formation.

[0244] Example 4: Broad and potent HIV neutralization

[0245] To evaluate the neutralizing activity of the new PGT121 variants, we used 10 virus strains (including R1166.c1, which lacks PNGS at gp120 position 332) to measure their ability to inhibit HIV infection of TZM-b1 cells. All PGT121 variants (including 10-1074-like antibodies) neutralized 9 pseudoviruses, and none neutralized the R1166.c1 control ( Figure 1 A and Table 4). Neutralization activity correlated with affinity for HIV spike, with the 10-1074 group showing slightly greater potency than the PGT121 group ( Figure 1 B and Figure 4 C). A representative germline version (GL) of the PGT121 / 10-1074 antibody clonotype was unable to bind gp120 / gp140 or neutralize any virus in this panel, suggesting that somatic mutations are required for binding and neutralization. Pairing the GL light chain with either the mutant 10-1074- or 10-996-group heavy chains failed to rescue binding or neutralization, suggesting that the two mutant chains contribute to the correct assembly of the antibody paratope.

[0246] The following assays were performed to compare the neutralizing activity of PGT121 and two 10-1074-like antibodies (10-996 and 10-1074) against an expanded panel of 119 difficult-to-neutralize pseudoviruses (classified as tier-2 and tier-3) (Tables 4 and 5). 10-996 and 10-1074 showed similar neutralizing potency and breadth to PGT121 ( Figure 1 C, Fig. 9, and Tables 5 and 6). As expected, most viruses carrying amino acid changes at gp120 positions 332 and / or 334 (spanning the Asn332-X-Ser334 / Thr334 PNGS) were resistant to neutralization (83.8% resistant to PGT121, 100% resistant to 10-1074 and 10-996). Mutations at this PNGS accounted for the majority of viruses resistant to neutralization (68.5% for 10-996, 72.5% for 10-1074 and 60.8% for PGT121) (Table 7). Comparable neutralizing activity was observed for the IgG and Fab forms of PGT121 and 10-1074, suggesting that bivalency is not critical for their activity ( Figure 1 D).

[0247] To evaluate the potential role of complex N-glycans on the HIV envelope in neutralization by PGT121 and 10-1074, we generated high-mannose-only virions in two different ways: by assembling pseudoviruses in cells treated with kifuncin (which generates Man9GlcNAc2 N-linked glycans), or by assembling pseudoviruses in HEK 293S GnTI cells. - / - 10-1074 resistant strains was assembled in cells (this generates Man5GlcNAc2 N-linked glycans). We found that PGT121 neutralized 2 of the 3 kifunine-derivatized PGT121-sensitive / 10-1074-resistant strains to the same extent as their counterparts generated in wild-type cells ( Figure 8 C) GnTI - / - The two PGT121-sensitive / 10-1074-sensitive virus strains generated in cells were equally sensitive to PGT121 and 10-1074 as their counterparts generated in wild-type cells. - / - Antibodies to the CD4 binding site of the virus produced in cells (NIH45-46 G54w and 3BNC60) are more sensitive ( Figure 8 D).

[0248] Example 5: Newly transmitted HIV-1

[0249] Next, we examined the activity of PGT121 and 10-1074 against transmission founder viruses by assessing neutralization in a peripheral blood mononuclear cell (PBMC)-based assay using cohorts of 95 clade B viruses (51, 52) isolated from individuals who seroconverted between 1985 and 1989 (historical seroconverters, n = 14) or between 2003 and 2006 (contemporary seroconverters, n = 25). We compared PGT121 and 10-1074 with anti-CD4bs bNAbs and other bNAbs, including VRC01, PG9 / PG16, b12, 2G12, 4E10, and 2F5. Cluster analysis of neutralization activity showed separation into two groups; the PGT121 / 10-1074 group contained the most active HIV neutralizers, including anti-CD4bs and PG9 antibodies (Table 8). Significantly, 10-1074 showed superior neutralization potency against this group of clade B viruses, exhibiting the greatest breadth of all bNAbs tested at 0.1 μg / ml (67% of 95 clade B viruses) (Table 8). Although 10-1074 showed higher potency against contemporary clade B viruses than PGT121 (approximately 20-fold difference), both antibodies were more effective against historical viruses than against contemporary viruses ( Figure 1 E and Fig.10 ).

[0250] Example 6: Crystal structures of PGT121, 10-1074 and GL

[0251] To investigate the structural determinants of the differences between PGT121-like and 1074-like antibodies, we used and The crystal structures of the Fab fragments of PGT121, 10-1074 and a representative germline precursor (GL) were solved at 1.340 Å resolution (Table 9). The variable domains of the heavy and light chains (V H and V L ) showed conservation of the main chain structure, with differences limited to small substitutions in the CDRH3 and CDRL3 loops of the affinity matured Fab relative to GL (Table 10).

[0252] A rare feature shared by antibodies is their long (25 residues) CDRH3 loop, which forms a double-stranded antiparallel β-sheet that extends V HThe F and G chains of the domains. In each Fab, the tip of the extended CDRH3 loop contains mainly nonpolar residues. Similar structural features were observed for the CDRH3 of PGT145, a carbohydrate-sensitive antibody whose epitope involves the gp120 V1V2 loop. However, the extended double-stranded β-sheet of CDRH3 of PGT145 contains mainly negatively charged residues, including two sulfated tyrosines at the tip. Comparison of the V1V2 loops of PGT121 and PGT145 shows that the V1V2 loops of PGT121 and PGT145 are not negatively charged. H -V L (Table 10) shows that CDRH3 PGT145 Extended beyond CDRH3 PGT121 , and its tip and V H The domains are aligned, and the CDRH3 of PGT121, 10-1074, and GL are oriented toward V L Tilt. CDRH3 PGT121 / CDRH3 10-1074 / CDRH3 GL To V L The tilt opens a cleft between CDRH2 and CDRH3, a feature not shared by related antibodies.

[0253] PGT121 and 10-1074 are highly divergent relative to GL and to each other (PGT121 has 132 residues in the VH With 10-1074 VH and GL VH differ by 36 and 45 residues, respectively, while 10-1074 VH and GL VH Most of the PGT121 / 10-1074 differences are located in the CDR VH Interestingly, the six substitutions in CDRH3 (residues 100d, 100f, 100h, 100j, 1001, 100n) alternate so that every second residue is substituted, which results in a shift from CDRH3 to V L Resurfacing of the cleft between the tilted CDRH2 and CDRH3. This region may contribute to the different subtle specificities of PGT121 and 10-1074. Heavy chain framework region 3 (FWR3 HC ) are potential antigen contact sites, given that the framework regions in HIV antibodies can contact gp120. Other differences that may contribute to subtle specificity differences include Asp56, which is not present in 10-1074 or GL. HC (10-1074 and Ser56 in GL HC) and the positive patches on the CDRL1 and CDRL3 surfaces that cannot be found on similar surfaces of GL.

[0254] Somatic mutations common to PGT121 and 10-1074 may contribute to the shared characteristics of their epitopes. The heavy chains of PGT121 and 10-1074 share only three common mutations (in 36 PGT121-GL and 29 10-1074-GL differences). In comparison, PGT121 and 10-1074 share 18 common light chain mutations (in 37 PGT121-GL and 36 10-1074-GL differences), including an insertion in light chain FWR3 (which introduces a bulge in the loop connecting chains D and E), and CDRL2 in both PGT121 and 10-1074. GL Asp50 LC -Asp51 LC To Asn50 LC -Asn51 LC Substitution (resulting in a less negatively charged surface). Introducing LC PGT121 and LC 10-1074 The large amount of co-substitution in (about 50% LC substitution) points to CDRL1, CDRL2 and FWR2 LC Potential contact regions for epitopes shared by PGT121 and 10-1074.

[0255] Next, the structure of PGT128 was compared, which recognizes Asn332 gp120 - and Asn301 gp120 -linked glycans and V3, and resolved in complex with the exodomain / mini V3 loop gp120 expressed in cells that are unable to produce complex N-glycan-modified proteins. Unlike the CDRH3 loops of PGT121 and 10-1074, PGT128 CDRH3 No PGT128 VL Tilt, and CDRH3 PGT128 The double-stranded β-sheet is not included. PGT128 (18 residues) is shorter than the CDRH3 of PGT121 and 10-1074 (24 residues), while CDRH2 PGT128 Contains a 6-residue insertion not found in PGT121 or 10-1074. Due to these differences, CDRH2 is the most prominent feature in PGT128, while CDRH3 is the most prominent in PGT121 and 10-1074. PGT128 and CDRL3 PGT128 Common recognition attached to Asn332 gp120 Man 8 / 9, and CDRH3 PGT128 This gp120 recognition model is not possible for PGT121 and 10-1074 because the structural features of their CDRH2 and CDRH3 loops differ significantly from those of PGT128, which is consistent with PGT128 but not PGT121 and 10-1074 ( Figure 7 ) were consistent with their ability to recognize protein-free high-mannose glycans.

[0256] Example 7: Crystal structure of PGT121-glycan complex

[0257] Using crystals obtained under conditions containing NA2, a complex asialyl biantennary glycan ( Figure 7 ) Analysis of PGT121 binding to complex sialylated biantennary glycans Surprisingly, the glycan bound to PGT121 in our crystal structure is not NA2, but rather a complex N-glycan from a neighboring PGT121 Fab in the crystal lattice; specifically, it is attached to Asn105 HC The glycan identity is evident from the presence of a HC The electron density for the glycosidic linkages and the terminal sialic acid on the Manα1-3Man antennae (the galactose and sialic acid modules of the Manα1-6Man antennae are unresolved). The composition of the bound glycans corresponds to the α2-6-sialylated A2(2-6) glycans in the microarray experiments ( Figure 7 ) bound by PGT121 and the expected sialyl linkages on the complex N-glycans corresponding to PNGS attached to proteins expressed in HEK293T cells. H -V L The domain overlaps with no significant difference to the V domain of the PGT121 structure without bound N-glycan (“ligand-free” PGT121). H -V L domain (Table 10), but the elbow bend angle (V H -V L and C H 1-C L The angle between the pseudo-dyads varies between structures. This difference may reflect flexibility, which allows the Fab to adopt variable elbow bend angles depending on lattice forces.

[0258] Given that we observed binding of complex N-glycans in one crystal structure (the “liganded” PGT121 structure) but not in the other (the “unliganded” PGT121 structure), we assessed the affinity of PGT121 for complex N-glycans not attached to gp120 over the concentration range of PGT121 in the crystal (approximately 10 mM). If we assume that the K for binding to isolated glycans is D In the range of 1-10 mM, it binds to PG9 with Man5GlcNAc2-Asn to give a K of 1.6 mM. D If the K of PGT121 binding to the isolated glycan is D represents only a minor contribution to the affinity of PGT121 for gp120, which is in the nM range ( Figure 4 A).

[0259] Glycans in the "liganded" PGT121 structure specifically bind to V H domains interact with each other and make extensive contacts with residues in all three CDRs The contacts include 10 direct and 18 water-mediated hydrogen bonds to the 9 amino acids of the glycan between the N-acetylglucosamine module anchored to the branch point mannose and the terminal sialic acid on the 1-3-antenna (Table 11). Several contacts to PGT121 are made through this sialic acid, with the water-mediated hydrogen bonds to Asp31 Hc In addition to the hydrogen bond with PGT121 residue Asp31 HC and His97 HC Sialic acid also contributes to the water-mediated intraglycan hydrogen bond network. Direct contacts with sialic acid may explain the stronger binding of PGT121 to sialylated A2(2-6) glycans than to non-sialylated NA2 glycans in our glycan microarray analysis ( Figure 7 Extensive water-mediated protein contacts established by 1-3-antennary N-acetylglucosamine and galactose modules could explain the observed binding of non-sialylated mono- and bi-antennary glycans to PGT121 ( Figure 7 ).

[0260] Six residues (Ser32 HC-CDRH1 , Lys53 HC-CDRH2 , Ser54 HC-CDRH2 , Asn58 HC-CDRH2 , His97 HC-CDRH3 , Thr1001 HC-CDRH3 ) and those residues at 10-1074 (Tyr32 HC-CDRH1 , Asp53 HC-CDRH2 , Arg54 HC-CDRH2 ,Thr58HC-CDRH2 , Arg97 HC-CDRH3 , Tyr1001 HC-CDRH3 ) and are highly conserved among PGT121-like but not 10-1074-like antibodies. Residues 10-1074 lack the corresponding functional groups to make the observed glycan contacts or have bulky side chains that would cause steric clashes. Four of these residues are identical to those on GL (Tyr32 HC-CDRH1 , Tyr53 HC-CDRH2 , Gln97 HC-CDRH3 , Tyr1001 HC-CDRH3 ), suggesting that the lack of binding of 10-1074-like antibodies and GL to protein-free complex glycans in our glycan microarrays stems from missing hydrogen bonds and / or steric clashes (e.g., His97 PGT121 Arg97 10-1074 ;Thr100I PGT121 Tyr1001 10-1074 Since most of the sequence differences between PGT121 and 10-1074 are clustered in the CDRH loops, particularly to the cleft surface between CDRH2 and CDRH3, where we observed bound complex N-glycans, differential recognition of complex glycans on gp120 may account for some or all of the observed differences in their subtle specificities.

[0261] Example 8: Substitution of glycan contacting antibody residues affects neutralization

[0262] To evaluate the contribution of complex N-glycan contact residues identified from the “liganded” PGT121 structure, we generated two mutant antibodies designed to exchange complex glycan contact residues between PGT121 and 10-1074: 10-1074 IgG with PGT121 residues (6 substitutions in IgH Y32S, D53K, R54S, T58N, R97H, Y1001T) and PGT121 IgG with the corresponding substitutions. GM and PGT121 GM ) exhibited near wild-type apparent affinity for YU-2 gp120 / gp140, as measured by SPR ( Figure 2 A), demonstrating that the substitutions did not disrupt binding to envelope synapses derived from strains neutralized by both PGT121 and 10-1074 ( Figure 1 A) The fact that PGT121 complex N-glycan contact residues can be accommodated in a 10-1074 context without disrupting binding to gp120 / gp140 bound by both wild-type antibodies suggests an overall similarity in antigen binding, albeit with subtle specificity differences.

[0263] Unlike wild-type PGT121, PGT121 GM No glycan binding was shown in the microarray experiments, confirming that residues 10-1074 at the substituted positions are incompatible with protein-free glycan binding ( Figure 2 B), and supports the suggestion that the glycan-contacting residues in the "liganded" PGT121 structure are involved in recognizing complex glycans in the microarray. 10-1074 GM No binding to protein-free glycans was shown either ( Figure 2 B), which indicates residues other than those substituted in the binding site that are involved in creating protein-free complexed N-glycans.

[0264] Next, we used a TZM-b1-based assay to compare neutralization by wild-type and “sugar mutant” antibodies. We tested 40 virus strains, including strains that were differentially resistant to PGT121 or 10-1074 and strains that were sensitive to both wild-type antibodies ( Figure 2 C and Table 12). GM and 10-1074 GM Consistent with binding to purified YU-2 envelope protein, both mutants neutralized YU-2 virus; however, 64% of the PGT121-susceptible strains were sensitive to PGT121. GM Resistant ( Figure 2 C, and Table 12), suggesting that the glycan contact residues identified in the "liganded" PGT121 structure are associated with the neutralizing activity of PGT121. GM Showed higher average efficacy against 10-1074-sensitive strains than wild-type 10-1074 ( Figure 2 C and Table 12), including a greater than 3-fold increase in potency against four 10-1074-sensitive strains (WITO4160.33, ZM214M.PL15, Ce1172_H1, and 3817.v2.c59). In general, PGT121 substitutions against 10-1074 did not confer efficacy against PGT121-sensitive / 10-1074-resistant strains. GM However, two of these strains (CNE19 and 62357_14_D3_4589) became sensitive to 10-1074 GM Sensitive (IC 50 = 0.19 μg / ml and 40.8 μg / ml, respectively). Interestingly, these were the only PGT121-sensitive / 10-1074-resistant strains that contained an intact Asn332 gp120 Other PGT121 sensitive / 10-1074 resistant strains lack Asn332 gp120-linked glycans, and for PGT121 GM and 10-1074 GM This suggests that the sensitivity to wild-type PGT121 involves compensation of nearby N-glycans and / or protein moieties of the epitope. GM Significant gain of function was observed, but this was consistent with the 10-1074-sensitive strains. GM The general improvement observed ( Figure 2 C) Together, this result is consistent with the interpretation that the glycan contact residues identified by crystallography can transfer PGT121-like recognition properties to 10-1074 in some contexts and / or affect its potency in other antibodies. GM The loss of neutralization activity against PGT121-sensitive strains demonstrated that the neutralization activity of PGT121 involves residues identified as contacting complex N-glycans in the "liganded" PGT121 structure.

[0265] result

[0266] PGT121 is a glycan-dependent bNAb that was originally identified in serum from a clade A infected donor in a functional screen that yielded only two clonally related members. Single-molecule sorting using gp140 trimers as "bait" isolated 29 novel clonal variants. The PGT121 clonal family includes different groups of closely related antibodies; the PGT121 and 10-1074 groups. The results suggest that the epitopes of these two groups involve Asn332 gp120 The PGT121-like and 10-1074-like antibody groups differ in amino acid sequence, gp120 / gpl40 binding affinity, and neutralization activity, with the 10-1074-like antibodies being completely dependent on Asn332 for neutralization. gp120 The intact PNGS at Asn332 is present, while PGT121-like antibodies can neutralize some gp120 Virus strains of PNGS.

[0267] The significant difference between the two antibody groups was that the PGT121-like antibodies bound complex N-glycans in the carbohydrate array, while the 10-1074-like antibodies showed no detectable binding to any of the protein-free N-glycans tested ( Figure 7). Protein-free glycan binding of anti-HIV antibodies is not always detectable; for example, although PG9 recognized gp120-bound high mannose glycans, no binding to protein-free glycans was detected in the microarray. Thus, although a positive result in the glycan microarray suggests that a particular glycan is incorporated into the antibody epitope, a negative result does not rule out glycan recognition. For example, although not detected in the glycan microarray experiment, high mannose glycans can participate in the PGT121 epitope, which is consistent with binding and neutralization of only the high mannose form of the gp120 protein to the virion ( Figure 8 ).

[0268] The molecular basis of the differences between PGT121, 10-1074 and their GL ancestors is partially revealed by their crystal structures. Most light chain somatic mutations are shared between PGT121 and 10-1074, while the findings of different mutations in the heavy chain suggest that the light chain contacts a portion of the shared gp120 epitope and that the heavy chain recognizes unique features. All three antibodies exhibit an extended CDRH3 with a nonpolar tip that allows access to a hidden epitope. The differences in the antigen binding sites of the two mature Fabs are primarily localized to the cleft between CDRH2 and the extended CDRH3. Interestingly, the putative antigen binding cleft between CDRH2 and CDRH3 was also found in the representative germline ancestors of PGT121 and 10-1074.

[0269] Structural information on glycan recognition of PGT121-like antibodies obtained from crystal structures in which the glycans attached to V H The complex sialylated N-glycans on the residues of the α2-6 domain interact with the adjacent PGT121 Fab assembly site. Several features of the "liganded" PGT121 structure suggest that it is relevant for understanding the complex N-glycans on gp120 recognized by PGT121-like antibodies. First, the glycans in the structure correspond to the α2-6 sialylated glycan A2(2-6) ( Figure 7 Second, the glycan interacts with PGT121 using the cleft between CDRH3 and CDRH2 that was suggested by structural analysis to be involved in epitope recognition, potentially explaining the role of CDRH3 in V in the PGT121 and 10-1074 structures. L Third, most of the Vs identified as interacting with glycans H The residues all differ between PGT121 and 10-1074, which rationalizes the different binding profiles in the glycan microarray and potentially explains the different subtle specificities revealed in the protein binding experiments. Fourth, the exchange crystallographically identified glycan contact residues between PGT121 and 10-1074 partially shift their properties: PGT121 GMLike 10-1074, it does not bind protein-free glycans, but PGT121 GM and 10-1074 GM Both retain near wild-type binding to purified YU-2 gp120 / gp140. GM It retained the ability to neutralize some virus strains neutralized by wild-type PGT121 and 10-1074, but it was unable to neutralize PGT121-sensitive / 10-1074-resistant strains, demonstrating that the glycan binding motif is essential for the neutralizing activity of PGT121 against 10-1074-resistant strains. GM The neutralizing potency of 10-1074 was either increased or unaffected, and in one case, 10-1074 GM Potently neutralized PGT121-sensitive / 10-1074-resistant strains, consistent with the shift in glycan motifs identified by crystallography and the hypothesis that the epitopes of PGT121 and 10-1074-like antibodies are related. In analysis of gp120 sequences from strains for which PGT121 neutralization data were available, no clear pattern of PNGS selection emerged for the different classes of strains (PGT121-sensitive / 10-1074-sensitive, PGT121-sensitive / 10-1074-resistant, PGT121-resistant / 10-1074-sensitive), except that 10-1074-resistant strains generally lacked PNGS associated with gp120 at Asn332.

[0270] Example 9: In vivo passive transfer of anti-HIV-1 neutralizing mAb

[0271] Five isolated potent and broadly acting anti-HIV neutralizing monoclonal antibodies were administered to macaques and challenged intrarectally with either of two different SHIVs 24 hours later. By combining the results obtained from 60 challenged animals, the protective neutralization titer in plasma obtained to block 50% of the virus in exposed monkeys was approximately 1:100.

[0272] Animal experiments

[0273] The macaques used in this study were negative for the MHC class I Mamu-A*01 allele.

[0274] Construction of R5-tropical SHIVDH12-V3AD8

[0275] These V3 sequences were introduced into the genetic background of the pSHIVDH12-CL7 molecular clone (J. of 2012) by PCR mutagenesis using Platinum PFX DNA polymerase (Invitrogen) with primers corresponding to the 5′ and 3′ halves of the gp120 V3 coding region of SHIVAD8EO (PNAS 109, 19769-19774 (2012)) (forward primer: AGAGCATTTTATACAACAGGAGACATAATAGGAGATATAAGACAAGCACATTGCAA CATTAGTAAAGTAAAATGGC and reverse primer: TCCTGGTCCTATATGTATACTTTTCCTTGTATTGTTGTTGGGTCTTGTACAATTAATTTCTACAGTTTCATTC). Virology 78, 5513-5519 (2004). After gel purification, the PCR product was treated with T4 polynucleotide kinase (GibcoBRL) and blunt-ended to create pSHIVDH12-V3AD8, which was used to transform competent cells.

[0276] Virus

[0277] Virus stocks were prepared by first transfecting 293T cells with SHIVAD8EO or SHIVDH12-V3AD8 molecular clones using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Culture supernatants were collected 48 hours later and aliquots were stored at -80°C until use. The cells were incubated with spinoculation (J. of Virology 74, (2000)) 1 hour later, supernatants from transfected cells were used to infect macaque PBMCs stimulated with concanavalin A (2 × 10 in 500 μl). 6 Cells), mixed with the same number / volume of activated PBMCs, and maintained for at least 12 days with daily medium changes. Samples of supernatant culture media were pooled around the time of peak RT generation to prepare separate virus stocks.

[0278] Antibody

[0279] Eleven monoclonal antibodies (VRC01, NIH45-46, 45-46G54W, 45-46m2, 3BNC117, 12A12, 1NC9, and 8ANC195, 10-1074, PGT121, and PGT126) were isolated and generated. DEN3 (a dengue virus NS1-specific human IgG1 monoclonal antibody) (PNAS 109, 18921-18925 (2012)) or control human IgG (NIH Nonhuman Primate Reagent Resource http: / / www.nhpreagents.org) were used as negative control antibodies in this study. Monoclonal antibodies selected for passive transfer before exposure were administered intravenously 24 hours before virus challenge.

[0280] Quantification of plasmid viral RNA levels.

[0281] Viral RNA levels in plasma were determined by real-time reverse transcription-PCR (ABIPrism 7900HT Sequence Detection System; Applied Biosystems).

[0282] Antibody concentration in plasma.

[0283] The concentration of the monoclonal antibody administered in monkey plasma was determined by enzyme-linked immunosorbent assay (ELISA) using recombinant HIV-1 JRFL gp120 (Progenics Pharmaceuticals) or HIVIIB (Advanced Biotechnology inc) (J. of Virology 75, 8340-8347 (2001)). Briefly, microtiter plates were coated with HIV-1 gp120 (2 μg / ml) and incubated overnight at 4°C. The plates were washed with PBS / 0.05% Tween-20 and blocked with 1% (vol / vol) BSA. After blocking, serial dilutions of the antibody or plasma samples were added to the plates and incubated at room temperature for 1 hour. Binding was detected with a goat anti-human IgG F(ab)2 fragment (Pierce) coupled to alkaline phosphatase and visualized with SIGMAFAST OPD (Sigma-Aldrich). Starting from the 5th or 7th day after antibody administration, the decay half-life of the neutralizing monoclonal antibody was calculated by a single exponential decay formula based on plasma concentration (J. of Virology 84, 1302-1313 (2010)).

[0284] Neutralization Assay.

[0285] The in vitro potency and neutralizing activity of each mAb present in plasma samples collected from macaques were evaluated by two types of neutralization assays; 1) TZM-b1 entry assay with pseudotyped challenge virus (AIDS Res Hum Retroviruses 26, 89-98 (2010)) or 2) 14-day PBMC replication assay with replication-competent virus (J. of virology 76, 2123-2130 (2002)). For the TZM-b1 assay, serially diluted mAbs or plasma samples were incubated with pseudotyped viruses expressing env genes derived from SHIVAD8EO or SHIVDH12-V3AD8 and prepared by co-transfecting 293T cells with pNLenv1 and pCMV vectors expressing the corresponding envelope proteins (J. of Virology 84, 4769-4781 (2010)). 50% neutralization inhibitory dose (IC50) titer is calculated as the dilution that causes 50% reduction of relative luminescence unit (RLU) compared with the level in virus control well after deducting cell control RLU (J. of Virology 84, 1439-1452 (2010)). Plasma samples from group studies (which exhibit a wide range of neutralization activity against subtype B HIV-1 isolates) were used to determine the neutralization phenotype (tier levels) of SHIVDH12:V3AD8 molecular clones by TZM-b1 cell assay (J. of General Virology 91, 2794-2803 (2010)).

[0286] Determination and statistical analysis of animal protective titers.

[0287] The neutralization titer in plasma for each R5SHIV that resulted in prevention of virus acquisition in 50 or 80% of animals challenged with the virus was calculated using the method of Reed and Muench (Am J Hyg 27, 493-497 (1938)). One significant outlier animal (DEW7) was omitted from the calculation. Using all 60 passively immunized monkeys, the relationship between the layers in plasma required to confer sterilizing immunity in vivo was modeled using Probit regression (Cambridge University Press, Cambridge, England, 3rd edition, 2007), and the p-value from this model was based on the Likelihood ratio Test. The plasma titers required for different levels of in vivo protection (33%, 50%, 80%, 90%, and 95%) were estimated from the Probit model, and 90% confidence intervals were constructed using bootstrapping.

[0288] result:

[0289] SHIVDH12-V3AD8 has two layers of anti-HIV-1 neutralization sensitivity characteristics like SHIVAD8EO (Table 13). Rhesus macaques inoculated intravenously or intrarectally with SHIVDH12-V3AD8 exhibited peak viremia ranging from 105 to 107 viral RNA copies / ml plasma at 2 to 3 weeks post-infection (PI). In most SHIVDH12-V3AD8-infected animals, plasma viral loads dropped to background levels between the 8th and 20th weeks post-infection.

[0290] The neutralization sensitivity of SHIVAD8EO to 11 recently reported broadly active anti-HIV-1 mAbs was initially determined in the TZM-b1 assay system ( Fig.11 A and B). Eight of these antibodies, VRC01, NIH45-46 (23), 45-46G54W, 45-46m2, 3BNC117, 12A12, 1NC9, and 8ANC195, target gp120 CD4 bs (Science 333, 1633-1637 (2011)), and three, 10-1074, PGT121, and PGT126 (Nature 477, 466-470 (2011)), are dependent on the presence of HIV-1 gp120 N332 glycan. When tested against SHIVAD8EO, all three glycan-dependent mAbs exhibited higher potency than the CD4 bs mAbs ( Fig.11A). IC50 values ​​of the three mAbs targeting the gp120 N332 glycan ranged from 0.09 to 0.15 μg / ml. CD4 bs mAbs exhibited a much wider range of IC50 neutralizing activity (0.14 to 6.34 μg / ml), with 3BNC117 being the most potent. A similar hierarchy of neutralizing mAb potency was also observed with SHIVDH12-V3AD8 (glycan dependency > CD4 bs dependency), but neutralizing activity was distributed over a much wider range (>100-fold) compared to the IC50 values ​​observed for SHIVAD8EO ( Fig.11 B) SHIVDH12-V3AD8 is slightly more sensitive to glycan-targeting mAbs and more sensitive to CD4 bs-neutralizing mAbs than SHIVAD8EO.

[0291] based on Fig.11 Based on the results shown in , five neutralizing mAbs were selected for pre-exposure passive transfer studies: VRC01 because it was the first CD4bs Nab of the newly isolated broadly acting Nabs to be characterized; CD4 bs mAbs 45-46m2 and 3BNC117, both of which exhibited strong neutralizing activity against SHIVAD8EO and SHIVDH12-V3AD8; and the gp120N332 glycan-dependent mAbs PGT121 and 10-1074.

[0292] The scheme for passive transfer experiment is to administer the neutralizing monoclonal antibody of reduced amount intravenously, and attack animals in the rectum after 24 hours.Add the following understanding, the purpose is to block virus acquisition: humanized anti-HIV monoclonal antibody can reduce its effectiveness and / or may induce allergic response to individual macaques, select the SHIV attack dose that is enough to establish the size of infection in vivo after single inoculation.In this regard, we have previously carried out the rectal titration of SHIVAD8 in macaques, and reported 1x103TCID50 (it is measured by the end point dilution in macaque PBMC) inoculation is equivalent to administering about 3 animal infection doses 50 (AID50) (J.of virology 86,8516-8526 (2012)).In fact, the single rectal inoculation of 3 AID50 has caused 10 in 10 macaques to be infected by SHIVAD8EO or SHIVDH12-V3AD8 and successfully established.

[0293] As a control for the first passive transfer experiment, animals were intravenously administered anti-dengue virus NS1 IgG1 monoclonal antibodies and attacked with SHIVAD8EO after 24 hours. These two monkeys (ML1 and MAA) were quickly infected and produced peak levels of plasma viremia at 2 weeks after infection. VRC01 is the first anti-HIV-1 neutralizing monoclonal antibody tested for protection against viral acquisition and is administered to two macaques at a dose of 50 mg / kg. One of the two vaccinated macaques (DEGF) was completely protected from SHIVAD8EO attack, with no evidence of plasma viremia or cell-associated viral DNA during the 45-week observation period. Another recipient (DEH3) of 50 mg / kg VRC01 was infected, but peak plasma viremia was delayed to the 5th week after infection. Two other macaques administered with a lower amount (20 mg / kg) of VRC01 were not protected from SHIVAD8EO attack. These results are summarized in Table 13.

[0294] Next, the protective properties of PGT121 against SHIVAD8EO challenge were examined. PGT121 is one of the most potent glycan-targeted neutralizing mAbs measured in the TZM-b1 assay ( Fig.11 Based on the results obtained with VRC01, it was chosen to start with an in vivo titration of PGT121 mAb at 20 mg / kg. Two challenged monkeys (KNX and MK4) resisted the SHIVAD8EO challenge. When lower amounts (i.e., 5 mg / kg, 1 mg / kg, or 0.2 mg / kg) of PGT121 were administered, 1 of 2, 2 of 2, and 0 of 2 animals were protected, respectively (Table 13).

[0295] The ability of VRC01 and PGT121 mAbs to block SHIVDH12-V3AD8 acquisition was similarly evaluated (Table 13). The results obtained with VRC01 were comparable to those observed with SHIVAD8EO challenge: 1 of 2 recipients at 30 mg / kg was protected from establishing SHIVDH12-V3AD8 infection. PGT121 mAb was considerably more potent than VRC01 in preventing SHIVDH12-V3AD8 acquisition: 2 of 2 recipients at 0.2 mg / kg PGT121 resisted infection. PGT121 also appeared to be slightly effective in preventing SHIVDH12-V3AD8 from in vivo infection of SHIVAD8EO (Table 13). This result is consistent with the 8-fold difference in the IC50 values ​​of PGT121 neutralizing the two SHIVs in the in vitro assay ( Fig.11 ).

[0296] The results of passive transfer of 10-1074, 3BNC117, or 45-46m2 neutralizing mAbs to macaques followed by challenge with SHIVAD8EO or SHIVDH12-V3AD8 are summarized in Table 13. 10-1074 mAb potently blocked in vivo acquisition of both SHIVs. CD4bs 3BNC117 and 45-46m2 mAbs were selected for passive transfer to macaques based on their ability to Fig.11 IC50 values ​​for these two SHIVs in in vitro neutralization experiments are shown in Table 13. 3BNC117 successfully blocked SHIVAD8EO infection in 2 of 2 monkeys at 5 mg / kg, but not in the other 2 animals given a 1 mg / kg dose (Table 13). This is similar to the results observed when the same amount of 3BNC117 was administered to macaques challenged with SHIVDH12-V3AD8: 1 of 2 was infected at 5 mg / kg; 1 of 2 was infected at 1 mg / kg.

[0297] Plasma samples collected at various times from passively transferred macaques were analyzed by HIV-1 gp120 ELISA to determine neutralizing mAb concentrations. In general, plasma concentrations of each mAb at the time of challenge (24 hours after antibody administration) correlated with the antibody dose administered (Table 13).

[0298] Fig.12 The relationship between plasma mAb concentration and in vivo protection is shown in Figure 13. Of the 5 neutralizing mAbs evaluated, PGT121 was clearly the most effective against both viruses, with SHIVDH12-V3AD8 showing slightly greater sensitivity to this mAb (2 of 2 monkeys were protected at a plasma concentration of 0.2 μg / ml). In comparison, a plasma concentration of almost 400 μg / ml VRC01 was required to protect 1 of 2 animals from the same SHIVDH12-V3AD8 challenge virus (Table 13). 3BNC117, the most potent CD4 bs mAb administered to macaques in this study, was approximately 6 to 10 times more effective than VRC01 in preventing the acquisition of either SHIV. Fig.12 , Table 13).

[0299] The calculated half-lives of PGT121, 10-1074, 3BNC117, and VRC01 mAbs were quite similar: 3.5 days, 3.5 days, 3.3 days, and 3.1 days, respectively. In comparison, the half-life of 45-46m2 was extremely short and could not be measured. Based on the plasma mAb concentrations in several macaques 24 hours after administration of 20 mg / kg of the humanized neutralizing mAb (i.e., approximately 250 μg / ml [Table 13]), the two monkeys that received 20 mg / kg of 45-46m2 had plasma mAb concentrations of only 15.0 and 17.6 μg / ml, which decayed by more than 95% relative to the other neutralizing mAbs in 24 hours.

[0300] When attacking macaques with SHIVAD8EO or SHIVDH12-V3AD8, the plasma samples collected 24 hours after the monoclonal antibody was used to measure the neutralization titer. As shown in Table 13, good correlation was observed between the antiviral plasma neutralization titer and the protection provided for SHIV infection. The use of two polysaccharide-dependent monoclonal antibodies (PGT121 and 10-1074) obviously resulted in the highest anti-HIV-1 neutralization activity titer when the virus was attacked. The titer measured in the acceptor of the 45-46m2 monoclonal antibody was not detected at the detection limit or due to its extremely short half-life in vivo.

[0301] The method described by Reed and Muench (Am J Hyg 27, 493-497 (1938)) was used to calculate the neutralization titer measured in plasma that was required to prevent 50% of the viruses in the challenged monkeys. These protective titers (Tables 15 and 16) were derived for 28 monkeys challenged with SHIVAD8EO or 32 monkeys challenged with SHIVDH12-V3AD8, respectively. The plasma neutralization titer required to protect 50% of the animals challenged with SHIVAD8EO or SHIVDH12-V3AD8 was calculated to be 1:115 and 1:96, respectively. Because these similar titers were obtained after: 1) SHIV challenge by the same route and inoculum size and 2) the administration of the same neutralizing monoclonal antibody set, the neutralization data from all 60 animals were combined and Probit regression was performed to examine the relationship between plasma neutralization titer and in vivo protection. As a further check, when a term for SHIV virus was included in the Probit regression model on all 60 macaques, there was no evidence of a difference between the two SHIV viruses (p = 0.16). When applied to the full group of 60 macaques, Probit regression estimated that a plasma neutralization titer of 1:104 would prevent virus acquisition in 50% of the animals. Probit analysis of the data also estimated that a 50% plasma neutralization titer of 1:57 or 1:329 would protect 33% or 80% of the exposed animals, respectively.

[0302] Example 10: Administration of neutralizing mAbs to an in vivo model of chronic HIV infection

[0303] Method summary: Initially, the neutralizing activity of broadly acting 3BNC11724 and 10-107423 neutralizing monoclonal antibodies against SHIVAD8EO was determined in the TZM-b1 cell system against SHIVAD8EO. The ability to block viral acquisition or control plasma viremia in chronically infected animals challenged with R5-tropical SHIVAD8EO was assessed by monitoring plasma viral load and cell-associated viral nucleic acid; the level of CD4+T cell subsets was measured by flow cytometry. Circulating viral variants were analyzed with SGA and antibody levels in plasma were determined. The plasma level of NAab was determined by neutralizing activity against HIV-1 pseudovirus preparations that were only susceptible to 10-1074 or 3BNC117.

[0304] result:

[0305] Two groups of chronic infection macaques were evaluated. The first group consisted of two clinically asymptomatic animals (DBZ3 and DC99A), which had been infected for 159 weeks and had a similar and significant decline in circulating CD4+T cells (Table 17). The scheme for treating ongoing SHIV infection was to co-administer 10-1074 and 3BNC117 at a dosage of 10mg / kg. When monoclonal antibodies were used, the plasma viral load in macaque DBZ3 and DC99A was 1.08x104 and 7.6x103 RNA copies / ml respectively. These two monkeys responded to the combined anti-HIV-1 monoclonal antibody treatment, and plasma viremia was immediately and rapidly reduced to undetectable levels within 7 to 10 days. The suppression of measurable SHIVAD8EO in the plasma of macaque DBZ3 and DC99A after a single administration of two monoclonal antibodies lasted for 27 and 41 days respectively. In each case, plasma viremia rebounded to the level before treatment.

[0306] The second group of three animals (DBX3, DCF1, and DCM8) were treated with two neutralizing antibodies (each of which was also infected with SHIVAD8EO for more than 3 years and had clinical symptoms of intermittent diarrhea or loss of appetite) (Table 17). At the time of monoclonal antibody administration, the level of circulating CD4+T cells in macaque DCM8 was only 43 cells / μl and slightly higher in animals DCF1 (105 cells / μl) and DBXE (158 cells / μl). Plasma viral load exceeded 105 RNA copies / ml in animals DBXE and DCF1, and was significantly lower in monkey DCM8 (1.59x103 RNA copies / ml). The administration of two monoclonal antibodies to monkey DBXE resulted in a biphasic decrease in viremia from 2.0x105 RNA copies on day 0 to a level that was undetectable in plasma on day 20. This was followed by the recovery of high levels of circulating virus in DBXE within a few days. Macaque DCM8, which had a more modest plasma viral load and very low numbers of circulating CD4+ T cells, experienced a rapid decline in viremia to undetectable levels between days 6 and 20 after initiation of mAb treatment. Finally, animal DCF1 (previously reported to have generated broadly reactive anti-HIV-1 NAbs) responded to combined mAb therapy by exhibiting a transient and relatively modest 27-fold decrease in plasma viremia by day 6, after which viral load returned to high pre-treatment levels.

[0307] Also before and after antibody administration, the viral RNA and DNA levels associated with PBMC were measured (Table 18). For each animal, the monoclonal antibody treatment resulted in a reduced level of cell-associated viral RNA, which was fully associated with the plasma viral load measurement. Due to the antibody treatment, no consistent pattern was observed for the cell-associated viral DNA level. The administration of neutralizing monoclonal antibodies to chronic SHIVAD8EO infected monkeys also had a beneficial effect on the circulating CD4+T cell levels (especially in animals with very high viral load). The CD4+T cell number in macaques DBXE and DCF1 increased 2 to 3 times during the monoclonal antibody-mediated viral suppression phase, but gradually decreased to the level before treatment because viremia became detectable again.

[0308] Plasma concentrations of each mAb were determined by measuring plasma neutralizing activity against selected HIV-1 pseudovirus strains that were sensitive to one or the other, but not both antibodies ( Fig.13 A). In each treated animal, suppression of SHIVAD8EO viremia was maintained until a threshold plasma mAb concentration of approximately 1 to 3 μg / ml was reached ( Fig.13B and 13C). This was true even for macaque DCF1, for which a moderate and transient decrease in plasma viral RNA levels was observed. Interestingly, the monoclonal antibodies administered to clinically symptomatic macaques DCM8 and DCF1 had a shortened half-life or were undetectable. As documented earlier, macaque DCM8 had extremely low CD4+T cell levels (43 cells / μl plasma), and macaque DCF1 had to be euthanized on day 56 after treatment initiation due to its deteriorating clinical condition. Autopsy of DCF1 revealed severe enteropathy characterized by disseminated gastrointestinal cryptosporidiosis, pancreatitis, and cholangitis.

[0309] SGA analysis is used to determine whether amino acid substitutions have been produced in the gp120 region previously shown to affect the sensitivity of 10-1074 or 3BNC117 monoclonal antibodies. In each case, the rebound virus present in the plasma after immunotherapy is constant. In order to further test the sensitivity of the virus that reappears, 10-1074 and 3BNC117 conjugate therapy (each 10mg / kg) are applied again to two monkeys (DBZ3 and DC99A) without clinical symptoms. The viral load in each animal drops rapidly again and becomes undetectable at the 7th day of the second immunotherapy cycle. Viremia is suppressed for 7 days in macaque DBZ3 and suppressed for more than 21 days in monkey DC99A. In a word, these results suggest that the virus after the first treatment cycle in these two animals reappears in the body monoclonal antibody level that represents insufficient, rather than the virus resistance selected by the antibody.

[0310] Table 3

[0311] Complete collection of PGT121 and 10-1074 clone variants

[0312]

[0313] VHmut and Vλmut indicate the total number of mutations in the VH and VL Ig genes. (-) and (+) indicate the number of negatively and positively charged amino acids in the Ig complementarity determining region (CDR3), respectively. Y indicates the number of tyrosine residues in IgH / L CDR3 (in green). 1 is based on Kabat nomenclature (IgBLAST, http: / / www.ncbi.nlm.nih.gov / Igblast). Acidic and basic are red and blue, respectively. FRW1_del, the number of deleted nucleotides in the framework region 1 (FRW1) of IgL. FRW3_Ins, the number of inserted nucleotides in the framework region 3 (FRW3). Color shading shows clone members with the same IgH sequence, and among them, the IgL sequence identity that defines the clone is indicated in bold. ' indicates representative antibody variants that were generated and analyzed. 10-266IgL was not cloned, and 10-1141IgG was not generated.

[0314] Table 4

[0315] In vitro TZM-b1 neutralization assay on basal panel

[0316]

[0317] Numbers indicate the IC achieved in the TZM-b1 neutralization assay 50 (Top) and IC 80 (Bottom) Antibody IgG concentration in μg / ml. IC 50 / 80 Values ​​are color coded and indicate increasing neutralization sensitivity from dark green to dark red. > indicates that the IC for a given virus was not reached at the concentration tested. 50 Murine leukemia virus (MuLV) and R1166.c1 (clade AE) were negative controls.

[0318] Table 5

[0319] In vitro TZM-b1 neutralization assay on the extended group - IC50 values

[0320]

[0321] Numbers indicate the IC achieved in the TZM-b1 neutralization assay 50 The concentration of antibody IgG in μg / ml. IC 50 Values ​​are color coded and indicate increasing neutralization sensitivity from dark green to dark red. > indicates that the IC for a given virus was not reached at the concentration tested. 50 .

[0322] Table 6

[0323] In vitro TZM-b1 neutralization assay on the expanded group - IC80 values

[0324]

[0325] Numbers indicate the IC achieved in the TZM-b1 neutralization assay 80 The concentration of antibody IgG in μg / ml. IC 80 Values ​​are color coded and indicate increasing neutralization sensitivity from dark green to dark red. > indicates that the IC for a given virus was not reached at the concentration tested. 80 .

[0326] Table 7

[0327] Neutralization sensitivity according to N332 PNGS

[0328]

[0329] Dots indicate the presence of aspartic acid and serine residues in positions 332 and 334, respectively. Mutations at positions 332 and 334 (HXB2 sequence numbering) are indicated with substituted amino acids. IC50 values ​​are color coded and increasing neutralization sensitivity in the TZM-b1 assay is indicated from dark green to dark red.

[0330] Table 8

[0331] PBMC-based in vitro neutralization assay

[0332]

[0333] Numbers indicate the antibody IgG concentration in μg / ml that achieved IC50 in the PBMC-based neutralization assay. 50 Values ​​are color coded and indicate increasing neutralization sensitivity from dark green to dark red. > indicates that the IC for a given virus was not reached at the concentration tested. 50 ND, not determined.

[0334] Table 9

[0335] Data collection and refinement statistics (molecular replacement)

[0336]

[0337] Data for each structure were obtained from a single crystal

[0338] The values ​​in brackets are for the highest resolution shell

[0339] Table 10

[0340] RMSD values ​​of the Cα alignment of Fab

[0341]

[0342] Table 11

[0343] Contacts between PGT121 Fab and bound glycans

[0344]

[0345] Hydrogen bond standard: bond distance <3.5. OHO / NHO angle >90°

[0346] *Contacts close to hydrogen bonding distance were cut off and included as possible interactions.

[0347] Table 12

[0348] In vitro neutralization activity of PGT121GM and 10-1074GM

[0349]

[0350] Numbers indicate IC achieved in TZM-b1 neutralization assay 50 The concentration of antibody IgG in μg / ml. IC 50 Values ​​are color coded and indicate increasing neutralization sensitivity from dark green to dark red. > indicates that the IC for a given virus was not reached at the concentration tested. 50 .

[0351] Table 13

[0352]

[0353] Table 14

[0354]

[0355] Values ​​are the serum dilutions that reduced the relative luminescence units (RLU) by 50% compared to virus control wells (no test sample).

[0356]

[0357]

[0358] Table 17

[0359]

[0360] Table 18

[0361]

[0362] The foregoing examples and description of preferred embodiments should be construed as illustrative, rather than limiting, of the present invention, as defined by the claims. As should be readily appreciated, various variations and combinations of the features listed above may be utilized without departing from the present invention as set forth in the claims. Such variations are not considered to depart from the scope of the present invention, and all such variations are intended to be included within the scope of the appended claims. All references cited herein are incorporated herein in their entirety by reference.

Claims

1. An isolated anti-HIV antibody or an antigen-binding portion thereof, comprising CDRH 1, CDRH 2, CDRH 3, CDRL 1, CDRL2 and CDRL 3, wherein the CDRH 1, CDRH 2, CDRH 3, CDRL 1, CDRL 2 and CDRL 3 comprise corresponding sequences of a CDR group selected from the group consisting of SEQ ID NO:39-44, SEQ ID NO:51-56, SEQ ID NO:63-68, SEQ ID NO:75-80, SEQ ID NO:81-86, SEQ ID NO:87-92, SEQ ID NO:93-98, SEQ ID NO:99-104 and SEQ ID NO:131-136.

2. The isolated anti-HIV antibody or antigen binding portion thereof of claim 1, wherein the heavy chain and light chain comprise the corresponding sequences of SEQ ID NOs: 3-4, SEQ ID NOs: 7-8, SEQ ID NOs: 11-12, SEQ ID NOs: 15-16, SEQ ID NOs: 17-18, SEQ ID NOs: 19-20, SEQ ID NOs: 21-22, SEQ ID NOs: 23-24, and SEQ ID NOs: 129-130.

3. The isolated anti-HIV antibody or antigen binding portion thereof of claims 1-2, wherein the antibody is a human antibody, a humanized antibody or a chimeric antibody.

4. An isolated nucleic acid comprising a sequence encoding the CDRs, heavy chain variable region, or light chain variable region of the anti-HIV antibody or antigen binding portion thereof of any one of claims 1 to 3.

5. A vector comprising the nucleic acid of claim 4.

6. A cultured cell comprising the vector of claim 5.

7. A pharmaceutical composition comprising (i) at least one anti-HIV antibody or antigen-binding portion thereof according to any one of claims 1 to 3, and (ii) a pharmaceutically acceptable carrier.

8. Use of a first therapeutic agent comprising a therapeutically effective amount of an anti-HIV antibody or antigen-binding portion thereof according to any one of claims 1 to 3 in the preparation of a pharmaceutical composition for preventing or treating HIV infection or HIV-related diseases in a patient in need of such prevention or treatment.

9. The use of claim 8, wherein the pharmaceutical composition further comprises a second therapeutic agent.

10. The use of claim 9, wherein the second therapeutic agent is an antiviral agent.

11. The use of claim 9, wherein the second therapeutic agent is a therapeutic agent selected from the group consisting of a non-nucleoside reverse transcriptase inhibitor, a protease inhibitor, an entry or fusion inhibitor, and an integrase inhibitor.

12. A method for producing an anti-HIV antibody or an antigen-binding portion thereof, comprising Obtaining the cultured cell of claim 6; The cells are cultured in a culture medium under conditions that allow expression of the polypeptide encoded by the vector and assembly of the antibody or antigen-binding portion thereof, and The antibody or antigen-binding portion thereof is purified from the cultured cells or the culture medium of the cells.